URAT1 inhibitor as well as preparation method and application thereof

A URAT1 inhibitor formulated as per formula (I) effectively reduces uric acid levels with minimal side effects, addressing the limitations of existing inhibitors by enhancing efficacy and safety in treating gout and hyperuricemia.

CN119059989APending Publication Date: 2024-12-03CHINA PHARM UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410176610.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-31
Filing Date
2024-02-08
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current URAT1 inhibitors on the market have limited efficacy in reducing uric acid levels and are associated with severe liver and kidney damage, limiting their clinical application.

Method used

Development of a URAT1 inhibitor represented by formula (I) and its derivatives, which effectively inhibits URAT1 activity with minimal toxic side effects, thereby reducing uric acid levels and treating conditions like gout and hyperuricemia.

Benefits of technology

The URAT1 inhibitor demonstrates high efficiency in lowering uric acid levels with reduced toxicity, providing a safer therapeutic option for gout and hyperuricemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119059989A_ABST
    Figure CN119059989A_ABST
Patent Text Reader

Abstract

The invention provides a URAT1 inhibitor as shown in a formula (I) and a preparation method and application thereof, and the URAT1 inhibitor has an efficient inhibition effect on URAT1 and can be used as a medicine for treating diseases such as gout and hyperuricemia. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a URAT1 (uric acid transporter 1) inhibitor, a preparation method and uses thereof, and in particular to a URAT1 inhibitor that can be used to treat diseases such as gout and hyperuricemia, a preparation method and uses thereof. Background Art

[0002] Gout is a multi-gene hereditary disease caused by both environmental and genetic factors. Due to reduced uric acid excretion and disordered purine metabolism, blood uric acid levels increase, and a large amount of urate crystals are deposited in the joints and surrounding tissues, triggering an acute inflammatory response, followed by joint disorders or deformities in the later stages. When urate is deposited in the kidneys, gouty nephropathy will occur, often complicated by cardiovascular and cerebrovascular diseases that are life-threatening. Gout is divided into primary gout (genetic, enzyme deficiency, etc.), secondary gout (chronic hemolytic anemia, hyperparathyroidism, various kidney diseases, etc.) and idiopathic gout. The pathogenesis of gout is still unclear, but hyperuricemia (HUA) is the most important biochemical basis of gout.

[0003] Hyperuricemia, as the "fourth high" after diabetes, hypertension, and hyperlipidemia, is the second largest metabolic disease after diabetes, but it has not been paid much attention and discussion by the Chinese people. Data from the "2021 China Hyperuricemia and Gout Trend White Paper" show that in recent years, hyperuricemia in my country has shown a significant upward and younger trend. The overall prevalence of hyperuricemia in my country is 13.3%, with about 177 million patients, and the overall incidence of gout is 1.1%, with about 14.66 million patients. Another data shows that nearly 60% of patients with hyperuricemia and gout in my country are young people aged 18-35.

[0004] The reabsorption and resecretion of uric acid in the kidney are mainly coordinated by two different types of uric acid transporters. One type is uric acid reabsorption proteins, including URAT1, glucose transporter 9 (GLUT9), organic anion transporter 4 (OAT4) and organic anion transporter 10 (OAT10), which work together to maintain the level of uric acid in human blood. Among them, UART1 was first discovered on the apical membrane of human renal proximal tubular epithelial cells by Enomoto et al. in 2002. It is an organic anion membrane transporter with 12 transmembrane domains encoded by the SLC22A12 gene. Compared with other transporters, URAT1 has a higher affinity and transport efficiency for urate. About 90% of uric acid in the kidney is reabsorbed back into the cells by URAT1. Therefore, uric acid reabsorption can be inhibited by inhibiting URAT1 to treat diseases such as gout and hyperuricemia.

[0005] So far, although the URAT1 inhibitors available on the market can control the increase of uric acid to a certain extent, their efficacy is not ideal and is accompanied by adverse reactions such as severe liver and kidney damage, which limits the clinical application of such drugs. Therefore, there is an urgent need to develop URAT1 inhibitors with good efficacy and few toxic side effects in clinical practice. Summary of the invention

[0006] In one aspect, the present invention provides a URAT1 inhibitor represented by formula (I),

[0007]

[0008] or a stereoisomer, solvate, prodrug, isotope-labeled substance, or pharmaceutically acceptable salt thereof,

[0009] in,

[0010] X 1 Selected from O, S, Se, NR 5 , CHR 5 , SO, SO2 or S(O)=NR 5 , where R 5 is selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl-substituted C1-C6 alkyl or C1-C6 alkanoyl;

[0011] X 2 , X 3 , X 4 , X 5 Each independently selected from N or CR 6 , where R 6 is independently selected at each occurrence from H, halogen, cyano, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or C1-C6 haloalkoxy;

[0012] A, B, Y, and Z are each independently selected from N or CR 7 , where R 7 Each occurrence is independently selected from H, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, cyano, nitro, C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted C1-C6 alkyl, C3-C6 cycloalkyloxy, C3-C6 cycloalkyl substituted C1-C6 alkoxy, COR 8 、CO2R 8 ,CONR 8 R 8’ NR 8 R 8’ 、SOR 9 or SO2R9 , R 8 R 8’ Each is independently selected from H, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, or C3-C6 cycloalkyl-substituted C1-C6 alkyl; R 9 C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, or C1-C6 alkyl substituted with C3-C6 cycloalkyl;

[0013] R 1 , R 2 , R 3 or R 4 Each is independently selected from H, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted 5-membered or 6-membered heteroaryl, optionally substituted 3-membered to 6-membered heterocyclic group, the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-C 10 Aryl, 5-membered or 6-membered heteroaryl, 3-membered to 6-membered heterocyclyl are optionally substituted by a group selected from the group consisting of H, halogen, OR 5 NR 8 R 8’ , C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted C1-C6 alkyl, CO2R 8 or CONR 8 R 8’ ;or

[0014] R 1 and R 2 , R 2 and R 3 , R 3 and R 4 Together with the carbon atom to which it is attached, it forms an optionally substituted C3-C6 carbocyclic ring or an optionally substituted 3- to 6-membered heterocyclic ring, wherein the C3-C6 carbocyclic ring or the 3- to 6-membered heterocyclic ring is optionally substituted by a group selected from the group consisting of H, halogen, OR 5 、C1~C6 alkyl、NR 8 R 8’ , C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted C1-C6 alkyl, CO2R 8 or CONR 8 R 8’ , the condition is R 1 , R 2 , R 3 and R 4 Not forming a cycloalkyl group or a heterocyclic group at the same time;

[0015] Q is selected from CH2, CO, SO or SO2.

[0016] In one aspect, the present invention provides a method for preparing a URAT1 inhibitor represented by formula (I).

[0017] In one aspect, the present invention provides a method for preventing and / or treating a URAT1-mediated disease using a URAT1 inhibitor represented by formula (I).

[0018] In one aspect, the present invention provides a method for preventing and / or treating diseases such as gout and / or hyperuricemia using a URAT1 inhibitor represented by formula (I).

[0019] Compared with the prior art, the beneficial effect of the present invention is that the URAT1 inhibitor disclosed in the present invention has a good inhibitory effect on URAT1, and while showing high efficiency in reducing uric acid levels, it also shows a small toxic and side effect effect. DETAILED DESCRIPTION

[0020] definition

[0021] As used in this specification, the following words and phrases generally have the meanings set forth below, unless the context in which they are used indicates otherwise.

[0022] As used herein, the term "alkyl" refers to a monovalent group having a straight or branched saturated hydrocarbon chain of 1 to 6 carbon atoms, more typically 1 to 5 carbon atoms, 1 to 4 carbon atoms, 1 to 3 carbon atoms, or 1 to 2 carbon atoms. This term is exemplified by groups such as methyl, ethyl, 1-propyl (n-propyl), 2-propyl (isopropyl), 1-butyl (n-butyl), 2-methyl-1-propyl (isobutyl), 2-butyl (sec-butyl), 2-methyl-2-propyl (tert-butyl), 1-pentyl (n-pentyl), 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, and the like.

[0023] As used herein, the term "alkenyl" refers to a linear or branched unsaturated hydrocarbon chain monovalent group having 2 to 6 carbon atoms (more typically 2 to 5 carbon atoms, 2 to 4 carbon atoms, 2 to 3 carbon atoms, or 2 carbon atoms) and having carbon-carbon double bonds (e.g., 1, 2 or 3 carbon-carbon double bonds). The term is exemplified by groups such as vinyl (i.e., -CH=CH2), propen-1-yl (i.e., -CH=CHCH3), propen-3-yl (or allyl, i.e., -CH2CH=CH2), propen-2-yl (i.e., -C(CH3)=CH2), butadienyl (including 1,2-butadienyl and 1,3-butadienyl), and the like.

[0024] As used herein, the term "alkynyl" refers to a linear or branched unsaturated hydrocarbon chain monovalent group having 2 to 6 carbon atoms (more typically 2 to 5 carbon atoms, 2 to 4 carbon atoms, 2 to 3 carbon atoms, or 2 carbon atoms) and having carbon-carbon triple bonds (e.g., 1, 2 or 3 carbon-carbon triple bonds). The term is exemplified by groups such as ethynyl (i.e., -C≡CH), propargyl (i.e., -CH2C≡CH), propynyl (i.e., -C≡CCH3), etc.

[0025] As used herein, the term "halogen" refers to fluorine, chlorine, bromine and iodine.

[0026] As used herein, the term "alkoxy" refers to an "alkyl-O-" group, wherein alkyl is as defined herein. This term is exemplified by groups such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, and the like.

[0027] As used herein, the term "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by halogen, wherein alkyl is as defined herein. The term is exemplified by groups such as trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2,2-trifluoroethyl, 1,1,-difluoroethyl, etc.

[0028] As used herein, the term "carbocycle" refers to a saturated or partially unsaturated, monocyclic non-aromatic carbocyclic ring system containing 3-6 ring carbon atoms. Examples of carbocycles include, but are not limited to, cyclopropane rings, cyclobutane rings, cyclopentane rings, cyclohexane rings, cyclobutene rings, cyclopentene rings, cyclohexene rings, cyclopentadiene rings, and the like.

[0029] As used herein, the term "cycloalkyl" refers to a monocyclic saturated hydrocarbon group having 3 to 6 carbon atoms as ring atoms. Examples of cycloalkyl include cyclopropane, cyclobutane, cyclopentane, cyclohexane.

[0030] As used herein, the term "heterocyclyl", "heterocycle" refers to a monocyclic saturated or partially unsaturated group having 3 to 6 ring atoms in the ring, wherein in addition to carbon atoms, the ring atoms also contain at least one heteroatom selected from oxygen, nitrogen and / or sulfur. Examples of heterocyclyl or heterocyclic groups include, but are not limited to, aziridine, azetidinyl, tetrahydropyrrolyl, piperidinyl, oxirane, oxetane, tetrahydrofuranyl, tetrahydropyranyl, thiirane, thietanyl, tetrahydrothienyl, tetrahydrothiopyranyl, tetrahydroimidazolyl, tetrahydropyrazolyl, tetrahydrooxazolyl, tetrahydroisoxazolyl, tetrahydrothiazolyl, tetrahydroisothiazolyl, piperazinyl, morpholinyl, dioxanyl, thioxanyl, dithianyl, dihydropyridinyl, etc.

[0031] As used herein, the term "therapeutically effective amount" refers to an amount sufficient to affect treatment as defined below when administered to a mammal in need of such treatment. The therapeutically effective amount will vary with the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the mode of administration, etc., and can be readily determined by one of ordinary skill in the art.

[0032] As used herein, the term "pharmaceutically acceptable salt" refers to salts that retain the biological effectiveness and properties of a given compound and are not biologically or otherwise undesirable. Pharmaceutically acceptable salts can be acid addition salts and / or base addition salts. Acid addition salts can be prepared from inorganic acids and organic acids. Salts derived from inorganic acids include hydrochloride, hydrobromide, sulfate, nitrate, phosphate, carbonate, bisulfate, hydrogen phosphate, dihydrogen phosphate, bicarbonate, etc.; salts derived from organic acids include formate, acetate, propionate, glycolate, pyruvate, oxalate, malate, malonate, succinate, maleate, fumarate, tartrate, citrate, benzoate, cinnamate, mandelate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, salicylate, lactate, nicotinate, lauryl sulfate, naphthalenesulfonate, camphorsulfonate, gluconate, glucuronate, oleate, palmitate, stearate, pamoate, trifluoroacetate, phenylacetate, mandelate or ferulate, etc. Base addition salts can be formed with inorganic bases or organic bases. Salts derived from inorganic bases include sodium, potassium, ammonium, calcium, magnesium, iron, zinc, copper, lithium, barium, aluminum salts and the like; salts derived from organic bases include salts formed with various primary, secondary and tertiary amines, for example, ethylamine, diethylamine, n-propylamine, isopropylamine, diethanolamine, meglumine, lysine, arginine, piperazine, piperidine, morpholine, tromethamine, choline and the like.

[0033] As used herein, the term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients comprising the formulation and / or the mammal to be treated therewith.

[0034] As used herein, the term "solvate" refers to an association or complex of one or more solvent molecules with a compound of the invention. Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine. The term "hydrate" refers to a complex in which the solvent molecule is water.

[0035] As used herein, the term "prodrug" refers to those compounds that readily undergo chemical changes under physiological conditions to provide compounds of the present invention. In addition, prodrugs can be converted into compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, when a prodrug is placed in a transdermal patch reservoir together with a suitable enzyme or chemical reagent, the prodrug can be slowly converted into a compound of the present invention.

[0036] Any formula or structure given herein, including Formula I or any formula disclosed herein, also represents unlabeled forms of the compound as well as isotopically labeled forms. These forms of the compound may also be referred to as "isotopically labeled" or "isotopically enriched analogs". An isotopically labeled compound has a structure as depicted herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that may be incorporated into the compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine, such as, but not limited to, 2 H (deuterium, D), 3 H (tritium), 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F. 36 Cl, 123 I and 125 I. Various isotope-labeled compounds of the present invention, for example, compounds into which a radioactive isotope (e.g. 3 H. 13 C and 14 C). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced with deuterium.

[0037] In one embodiment, the present invention provides a URAT1 inhibitor as shown in (I) or a stereoisomer, solvate, prodrug, isotope label, and pharmaceutically acceptable salt thereof, wherein X 1 , X2 , X 3 , X 4 , X 5 , R 1 , R 2 , R 3 , R 4 , A, B, Y, Z, Q are as defined herein.

[0038] In one embodiment, X 1 Selected from O, S, NR 5 , CHR 5 , SO, SO2 or S(O)=NR 5 , where R 5 Selected from H, C1-C3 alkyl, C2-C3 alkenyl, C3-C6 cycloalkyl, C1-C3 alkyl substituted with C3-C6 cycloalkyl or C1-C3 alkanoyl.

[0039] In one embodiment, X 1 Selected from O, S, SO, SO2 or S(O)=NR 5 , where R 5 Selected from H, C1-C3 alkyl, C3-C6 cycloalkyl.

[0040] In one embodiment, X 1 Selected from O, S, SO, SO2 or S(O)=NR 5 , where R 5 is selected from H, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl or cyclopentyl.

[0041] In one embodiment, X 1 Selected from O, S, SO, SO2 or S(O)=NH.

[0042] In one embodiment, X 2 , X 3 , X 4 , X 5 Each independently selected from N or CR 6 , where R 6 Each occurrence is independently selected from H, halogen, cyano, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, or C1-C3 haloalkoxy.

[0043] In one embodiment, X 2 , X 3 , X 4 , X 5 Each independently selected from N or CR 6 , where R 6and is independently selected at each occurrence from H, F, Cl, Br, cyano, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2,2-trifluoroethyl, 1,1,-difluoroethyl, trifluoromethoxy, difluoromethoxy, monofluoromethoxy, 2,2,2-trifluoroethoxy, 1,1,-difluoroethoxy.

[0044] In one embodiment, X 2 , X 3 , X 4 , X 5 are each independently selected from N or CH.

[0045] In one embodiment, Y and Z are each independently selected from N or CR 7 , where R 7 Each occurrence is independently selected from H, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, cyano, nitro, C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted C1-C3 alkyl, C3-C6 cycloalkyloxy, C3-C6 cycloalkyl substituted C1-C3 alkoxy, COR 8 、CO2R 8 ,CONR 8 R 8’ NR 8 R 8’ 、SOR 9 or SO2R 9 , R 8 or R 8’ Each is independently selected from H, C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, or C1-C3 alkyl substituted with C3-C6 cycloalkyl; R 9 It is selected from C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, or C1-C3 alkyl substituted with C3-C6 cycloalkyl.

[0046] In one embodiment, Y and Z are each independently selected from N or CR 7 , where R 7 Each occurrence is independently selected from H, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, cyano, nitro, cyclopropyl, cyclopropyl-CH2-, cyclopropyloxy, cyclopropyl-CH2O-, COR 8 、CO2R 8 ,CONR 8 R 8’ NR 8 R 8’ 、SOR9 or SO2R 9 , R 8 or R 8’ R is independently selected from H, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1-difluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl-CH2-, cyclobutyl-CH2-, cyclopentyl-CH2-, or cyclohexyl-CH2-; 9 Selected from methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1-difluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl-CH2-, cyclobutyl-CH2-, cyclopentyl-CH2-, or cyclohexyl-CH2-.

[0047] In one embodiment, Y and Z are each independently selected from N or CR 7 , where R 7 At each occurrence it is independently selected from H, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, cyano, nitro, cyclopropyl, cyclopropyl-CH2-, cyclopropyloxy, cyclopropyl-CH2O-, CO2CH3, CO2C2H5, CONH2 or CONHCH3.

[0048] In one embodiment, Y and Z are each independently selected from N or CR 7 , where R 7 Each occurrence is independently selected from H, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, cyano, and nitro.

[0049] In one embodiment, Y and Z are each independently selected from N or CR 7 , where R 7 and is independently selected at each occurrence from H, F, Cl, Br, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2,2-trifluoroethyl, 1,1,-difluoroethyl, trifluoromethoxy, difluoromethoxy, monofluoromethoxy, 2,2,2-trifluoroethoxy, 1,1,-difluoroethoxy, cyano, and nitro.

[0050] In one embodiment, Y and Z are each independently selected from N or CR 7 , where R 7 Each occurrence is independently selected from H, F, Cl, Br, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2,2-trifluoroethyl, 1,1,-difluoroethyl, cyano, nitro.

[0051] In one embodiment, A and B are each independently selected from N or CR 7 , where R 7 Each occurrence is independently selected from H, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, cyano, nitro, C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted C1-C3 alkyl, C3-C6 cycloalkyloxy, C3-C6 cycloalkyl substituted C1-C3 alkoxy, COR 8 、CO2R 8 ,CONR 8 R 8’ NR 8 R 8’ 、SOR 9 or SO2R 9 , R 8 or R 8’ Each is independently selected from H, C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, or C1-C3 alkyl substituted with C3-C6 cycloalkyl; R 9 C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, or C1-C3 alkyl substituted with C3-C6 cycloalkyl;

[0052] In one embodiment, A and B are each independently selected from N or CR 7 , where R 7 Each occurrence is independently selected from H, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, cyano, nitro, cyclopropyl, cyclopropyl-CH2-, cyclopropyloxy, cyclopropyl-CH2O-, COR 8 、CO2R 8 ,CONR 8 R 8’ NR 8 R 8’ 、SOR 9 or SO2R 9 , R 8 or R 8’ R is independently selected from H, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1-difluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl-CH2-, cyclobutyl-CH2-, cyclopentyl-CH2-, or cyclohexyl-CH2-; 9Selected from methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1-difluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl-CH2-, cyclobutyl-CH2-, cyclopentyl-CH2-, or cyclohexyl-CH2-.

[0053] In one embodiment, A and B are each independently selected from CR 7 , where R 7 At each occurrence it is independently selected from H, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, cyano, nitro, cyclopropyl, cyclopropyl-CH2-, cyclopropyloxy, cyclopropyl-CH2O-, COCH3, SO2CH3, SO2CF3, CO2CH3, CO2C2H5, CONH2 or CONHCH3.

[0054] In one embodiment, A and B are each independently selected from CR 7 , where R 7 Each occurrence is independently selected from H, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, cyano, and nitro.

[0055] In one embodiment, A and B are each independently selected from CR 7 , where R 7 and is independently selected at each occurrence from H, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2,2-trifluoroethyl, 1,1,-difluoroethyl, trifluoromethoxy, difluoromethoxy, monofluoromethoxy, 2,2,2-trifluoroethoxy, 1,1-difluoroethoxy, cyano, and nitro.

[0056] In one embodiment, A and B are each independently selected from CR 7 , where R 7 Each occurrence is independently selected from H, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2,2-trifluoroethyl, 1,1-difluoroethyl, cyano, nitro.

[0057] In one embodiment, R 1 , R 2 , R 3 or R 4Each is independently selected from H, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, optionally substituted C3-C6 cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl, optionally substituted 3- to 6-membered heterocyclyl, wherein the C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C3-C6 cycloalkyl, phenyl, 5- or 6-membered heteroaryl, 3- to 6-membered heterocyclyl is optionally substituted by a group selected from the following: H, halogen, OR 5 NR 8 R 8’ , C3-C6 cycloalkyl, C1-C3 alkyl substituted with C3-C6 cycloalkyl, CO2R 8 or CONR 8 R 8’ ;or

[0058] R 1 and R 2 , R 2 and R 3 , R 3 and R 4 Together with the carbon atom to which it is attached, it forms an optionally substituted C3-C6 carbocyclic ring or an optionally substituted 3- to 6-membered heterocyclic ring, wherein the C3-C6 carbocyclic ring or the 3- to 6-membered heterocyclic ring is optionally substituted by a group selected from the group consisting of H, halogen, C1-C6 alkyl, OR 5 NR 8 R 8’ , C3-C6 cycloalkyl, C1-C3 alkyl substituted with C3-C6 cycloalkyl, CO2R 8 or CONR 8 R 8’ , the condition is R 1 , R 2 , R 3 and R 4 A carbocyclic ring or a heterocyclic ring cannot be formed at the same time.

[0059] In one embodiment, R 1 , R 2 , R 3 or R 4 each independently selected from H, methyl, ethyl, n-propyl, isopropyl, vinyl, propenyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, azetidinyl, oxetanyl, tetrahydropyrrolyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydroimidazolyl, tetrahydropyrazolyl, tetrahydrooxazolyl, tetrahydrothiazolyl, dioxanyl, morpholinyl, furanyl, imidazolyl, pyrazolyl, pyrrolyl, thienyl, thiazolyl, optionally substituted with a group selected from H, halogen, OR 5 NR 8 R8’ , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C3~C6 cycloalkyl-CH2-, CO2R 8 or CONR 8 R 8’ ;or

[0060] R 1 and R 2 , R 2 and R 3 , R 3 and R 4 Together with the carbon atom to which it is attached, it forms an optionally substituted cyclopropane ring, cyclobutane ring, cyclopentane ring, cyclohexane ring, azetidine ring, oxetane ring, tetrahydropyrrole ring, piperidine ring, tetrahydrofuran ring, tetrahydropyran ring, tetrahydrothiophene ring, tetrahydrothiopyran ring, tetrahydroimidazole ring, tetrahydropyrazole ring, tetrahydrooxazole ring, tetrahydrothiazole ring, dioxane ring, morpholine ring, which is optionally substituted by a group selected from the following: H, halogen, C1-C3 alkyl, OR 5 NR 8 R 8’ , C3-C6 cycloalkyl, C1-C3 alkyl substituted with C3-C6 cycloalkyl, CO2R 8 or CONR 8 R 8’ , the condition is R 1 , R 2 , R 3 and R 4 The above-mentioned carbocyclic ring or heterocyclic ring is not formed at the same time.

[0061] In one embodiment, R 1 , R 2 , R 3 or R 4 Each is independently selected from H, methyl, ethyl, n-propyl, isopropyl, vinyl, propenyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl; or

[0062] R 1 and R 2 , R 2 and R 3 , R 3 and R 4 Together with the carbon atom to which it is connected, it forms a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, or a cyclohexane ring.

[0063] In one embodiment, R 1 , R 2 , R 3 or R 4 are each independently selected from H; or

[0064] R 1 and R2 , R 3 and R 4 Together with the carbon atom to which it is connected, it forms a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, or a cyclohexane ring.

[0065] In one embodiment, R 1 , R 2 , R 3 or R 4 are each independently selected from H; or

[0066] R 1 and R 2 Together with the carbon atom to which it is attached, it forms a cyclopropane ring, R 3 and R 4 Selected from H.

[0067] In one embodiment, Q is selected from CO or SO2.

[0068] In one embodiment, Q is selected from CO.

[0069] In one embodiment, the URAT1 inhibitor represented by formula (I) is a compound represented by formula (II) or formula (II'):

[0070]

[0071] or its stereoisomers, solvates, prodrugs, isotope-labeled substances, and pharmaceutically acceptable salts, wherein X 1 , R 1 , R 2 , R 3 , R 4 , A, B, Y, Z, Q are as defined herein.

[0072] In one embodiment, the URAT1 inhibitor represented by formula (I) is a compound represented by formula (III) or formula (III'):

[0073]

[0074] or its stereoisomers, solvates, prodrugs, isotope-labeled substances, and pharmaceutically acceptable salts, wherein X 1 , R 1 , R 2 , A, B, Y, Z, Q are as defined herein.

[0075] In one embodiment, the URAT1 inhibitor represented by formula (I) is a compound represented by formula (IV) or formula (IV'):

[0076]

[0077] or its stereoisomers, solvates, prodrugs, isotope-labeled substances, and pharmaceutically acceptable salts, wherein X 1 , R 1 , R 2 , A, B, Y, and Z are as defined herein.

[0078] In one embodiment, the URAT1 inhibitor represented by formula (I) is a compound represented by formula (V-1), formula (V-2) and / or formula (V-3):

[0079]

[0080] or its stereoisomers, solvates, prodrugs, isotope-labeled substances, and pharmaceutically acceptable salts, wherein X 1 , R 1 , R 2 , R 7 As defined herein.

[0081] In one embodiment, the URAT1 inhibitor represented by formula (I) is a compound represented by formula (VI-1), (VI-2), (VI-3), (VI-4), (VI-5) and / or formula (VI-6)

[0082]

[0083] or a solvate, a prodrug, an isotope-labeled substance, or a pharmaceutically acceptable salt thereof, wherein X 1 , R 7 As defined herein.

[0084] In one embodiment, the compound represented by formula (I) is selected from any of the following compounds:

[0085]

[0086]

[0087] or a solvate, a prodrug, an isotope-labeled substance, or a pharmaceutically acceptable salt thereof.

[0088] The present invention provides a pharmaceutical composition comprising a compound of the present invention or its stereoisomer, solvate, prodrug, isotope label, pharmaceutically acceptable salt, and at least one pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are known to those skilled in the art, including diluents, lubricants, disintegrants, adhesives, buffers, preservatives, stabilizers, wetting agents, glidants, emulsifiers, colorants, flavoring agents, sweeteners, etc. Depending on the different routes of administration of the drug, such as oral administration, parenteral administration, and rectal administration, the pharmaceutical composition of the present invention can be made in solid form (including but not limited to tablets, capsules, pills, granules, powders, powders, suppositories) or liquid form (including but not limited to solutions, suspensions, emulsions, tinctures, syrups). When the pharmaceutical composition of the present invention is in solid form, the pharmaceutically acceptable carrier generally includes one or more of the following: a) diluents, such as lactose, glucose, sucrose, mannitol, sorbitol, cellulose, etc.; b) lubricants, such as silicon dioxide, talc, stearic acid, polyethylene glycol, etc.; c) binders, such as magnesium aluminosilicate, gelatinized starch, gelatin, tragacanth gum, methylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, etc.; d) disintegrants, such as starch, alginic acid, agar, corn starch; e) stabilizers, such as antioxidants such as ascorbic acid; f) glidants, such as silicon dioxide; g) flavoring agents, such as mint, methyl salicylate; sweeteners, such as sucrose, saccharin. When the pharmaceutical composition of the present invention is in liquid form, the pharmaceutically acceptable carrier generally includes one or more of the following: a) a diluent, such as water for injection, physiological saline, Ringer's solution, polyethylene glycol, glycerol, propylene glycol, etc.; b) an antioxidant, such as ascorbic acid or sodium bisulfite; c) a buffer, such as acetate, phosphate, etc.

[0089] The present invention also provides a method for preventing and / or treating a disease mediated by URAT1, comprising administering to an individual in need thereof a therapeutically effective amount of a compound of the present invention or its stereoisomer, solvate, prodrug, isotope label, pharmaceutically acceptable salt, or a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention or its stereoisomer, solvate, prodrug, isotope label, pharmaceutically acceptable salt, and at least one pharmaceutically acceptable carrier. The present invention also provides a method for preventing and / or treating diseases such as gout and hyperuricemia, comprising administering to an individual in need thereof a therapeutically effective amount of a compound of the present invention or its stereoisomer, solvate, prodrug, isotope label, pharmaceutically acceptable salt, or a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention or its stereoisomer, solvate, prodrug, isotope label, pharmaceutically acceptable salt, and at least one pharmaceutically acceptable carrier.

[0090] In some embodiments, the therapeutically effective amount is from about 1 mg to about 1500 mg. In some embodiments, the therapeutically effective amount is from about 1 mg to about 1000 mg. In some embodiments, the therapeutically effective amount is from about 1 mg to about 750 mg. In some embodiments, the therapeutically effective amount is from about 1 mg to about 500 mg. In some embodiments, the therapeutically effective amount is from about 1 mg to about 400 mg. In some embodiments, the therapeutically effective amount is from about 1 mg to about 300 mg. In some embodiments, the therapeutically effective amount is from about 1 mg to about 200 mg. In some embodiments, the therapeutically effective amount is from about 1 mg to about 100 mg. In some embodiments, the therapeutically effective amount is from about 1 mg to about 50 mg. In some embodiments, the therapeutically effective amount is from about 1 mg to about 25 mg. In some embodiments, the therapeutically effective amount is from about 5 mg to about 25 mg.

[0091] The present invention provides a use of a URAT1 inhibitor represented by formula (I) in preparing a medicament for preventing and / or treating a disease mediated by URAT1. The present invention also provides a use of a URAT1 inhibitor represented by formula (I) in preparing a medicament for preventing and / or treating a disease such as gout and / or hyperuricemia.

[0092] General synthetic method

[0093] Compounds of the present invention can be prepared using methods disclosed herein and their modified approaches and methods well known in the art. Typical embodiments of compounds according to the present invention can be synthesized using the general reaction scheme of the following arbitrary method. It is apparent from the description herein that corresponding different products can be obtained by replacing reaction raw materials with other materials having similar structures. Reaction raw materials are typically obtained from commercial sources or synthesized using disclosed methods.

[0094] Reaction Scheme I

[0095] When X 1 Represents SO, X 2 , X 3 , X 4 and X 5 Represents CH, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a cyclopropyl group, R 3 and R 4 represents H, Q represents CO, and the synthetic route of formula IA is:

[0096]

[0097] Wherein Y, Z, A and B are as defined in the text.

[0098] Specifically, compound b first reacts with a chlorinating agent to generate an acyl chloride compound, and then reacts with compound a to prepare compound c, wherein the chlorinating agent is selected from oxalyl chloride, phosphorus oxychloride, phosphorus trichloride, phosphorus pentachloride or thionyl chloride; preferably, the chlorinating agent is selected from thionyl chloride; the solvent used is selected from N,N-dimethylformamide, N,N-diethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, acetone, tetrahydrofuran or a mixed solvent composed of the above solvents; preferably, the solvent is selected from tetrahydrofuran; the reaction temperature is -5°C to 25°C; preferably, the reaction temperature is 0°C.

[0099] Compound d is prepared by reacting compound c with an oxidant, wherein the oxidant is selected from meta-chloroperbenzoic acid or hydrogen peroxide; preferably, the oxidant is selected from meta-chloroperbenzoic acid; the solvent is selected from dichloromethane, chloroform, ethyl acetate, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide or a mixed solvent of any two thereof; preferably, the solvent is selected from N,N-dimethylformamide; the reaction temperature is -5°C to 25°C; preferably, the reaction temperature is 0°C.

[0100] Compound IA is prepared by reacting compound d with a demethylation agent, wherein the demethylation agent is selected from lithium chloride, aluminum chloride, boron tribromide, hydrobromic acid, hydroiodic acid or pyridine hydrochloride; preferably, the demethylation agent is selected from lithium chloride; the solvent is selected from N,N-dimethylformamide, N,N-diethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide or a mixed solvent composed of the above solvents; preferably, the solvent is selected from N,N-dimethylformamide; the reaction temperature is 100°C to 140°C; preferably, the reaction temperature is 130°C.

[0101] Reaction Scheme II

[0102] When X 1 Represents SO2, X 2 , X 3 , X 4 and X 5 Represents CH, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a cyclopropyl group, R 3 and R 4 represents H, Q represents CO, and the synthetic route of formula IB is:

[0103]

[0104] wherein Y, Z, A and B are as defined herein.

[0105] Specifically, compound e is prepared by reacting compound c with an oxidant, and the oxidant used is selected from meta-chloroperbenzoic acid or hydrogen peroxide; preferably, the oxidant used is selected from meta-chloroperbenzoic acid; the solvent used is selected from dichloromethane, chloroform, ethyl acetate, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide or a mixed solvent of any two thereof; preferably, the solvent used is selected from N,N-dimethylformamide; the reaction temperature is 0°C to 30°C; preferably, the reaction temperature is 25°C.

[0106] Compound IB is prepared by reacting compound e with a demethylation agent, wherein the demethylation agent is selected from lithium chloride, aluminum chloride, boron tribromide, hydrobromic acid or hydroiodic acid; preferably, the demethylation agent is selected from lithium chloride; the solvent is selected from N,N-dimethylformamide, N,N-diethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, isopropanol, ethanol or a mixed solvent composed of the above solvents; preferably, the solvent is selected from N,N-dimethylformamide; the reaction temperature is 100°C to 140°C; preferably, the reaction temperature is 130°C.

[0107] Reaction Scheme III

[0108] When X 1 represents O=S=NH, X 2 , X 3 , X 4 and X 5 Represents CH, R 1 , R 2 , R 3 and R 4 Represents H;

[0109] Q represents CO, and the synthetic route of formula IC is:

[0110]

[0111] wherein Y, Z, A and B are as defined herein.

[0112] Specifically, compound b first reacts with a chlorinating agent to generate an acyl chloride compound, and then reacts with compound f to prepare compound g, wherein the chlorinating agent is selected from oxalyl chloride, phosphorus oxychloride, phosphorus trichloride, phosphorus pentachloride or thionyl chloride; preferably, the chlorinating agent is selected from thionyl chloride; the solvent used is selected from N,N-dimethylformamide, N,N-diethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, acetone, tetrahydrofuran or a mixed solvent composed of the above solvents; preferably, the solvent used is selected from tetrahydrofuran; the reaction temperature is -5°C to 25°C; preferably, the reaction temperature is 0°C.

[0113] Compound h is prepared by reacting compound g with an ammonia source and iodobenzenediacetic acid, wherein the ammonia source is selected from ammonia gas, ammonium carbamate or ammonium carbonate; preferably, the ammonia source is selected from ammonium carbamate; the solvent used is selected from N,N-dimethylformamide, N,N-diethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, acetone, isopropanol, tetrahydrofuran, ethanol or a mixed solvent composed of the above solvents; preferably, the solvent used is selected from methanol; the reaction temperature is 0°C to 30°C; preferably, the reaction temperature is 25°C.

[0114] Compound IC is prepared by reacting compound h with a demethylation agent, wherein the demethylation agent is selected from lithium chloride, aluminum chloride, boron tribromide, hydrobromic acid or hydroiodic acid; preferably, the demethylation agent is selected from lithium chloride; the solvent is selected from N,N-dimethylformamide, N,N-diethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, isopropanol, ethanol or a mixed solvent composed of the above solvents; preferably, the solvent is selected from N,N-dimethylformamide; the reaction temperature is 100°C to 140°C; preferably, the reaction temperature is 130°C.

[0115] Reaction Scheme IV

[0116] When X 1 Represents S, X 2 , X 3 , X 4 and X 5 Represents CH, R 1 and R 2 The carbon atom to which it is attached forms a cyclopropane

[0117] Ji, R 3 and R 4 represents H, Q represents CO, and the synthetic route of formula ID is:

[0118]

[0119] wherein Y, Z, A and B are as defined herein.

[0120] Compound ID is prepared by reacting compound c with a demethylation agent, wherein the demethylation agent is selected from lithium chloride, aluminum chloride, boron tribromide, hydrobromic acid or hydroiodic acid; preferably, the demethylation agent is selected from lithium chloride; the solvent is selected from N,N-dimethylformamide, N,N-diethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, isopropanol, ethanol or a mixed solvent composed of the above solvents; preferably, the solvent is selected from N,N-dimethylformamide; the reaction temperature is 100°C to 140°C; preferably, the reaction temperature is 130°C.

[0121] Reaction Scheme V

[0122] When X 1 Represents O, X 2Represents CH or N, X 3 , X 4 and X 5 Represents CH, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a cyclopropyl group, R 3 and R 4 represents H, Q represents CO, and the synthetic route of formula IE is:

[0123]

[0124] Among them, Y, Z, X 2 , A and B are as defined in the text.

[0125] Specifically, compound b first reacts with a chlorinating agent to generate an acyl chloride compound, and then reacts with compound i to prepare j, wherein the chlorinating agent is selected from oxalyl chloride, phosphorus oxychloride, phosphorus trichloride, phosphorus pentachloride or thionyl chloride; preferably, the chlorinating agent is selected from thionyl chloride; the solvent used is selected from N,N-dimethylformamide, N,N-diethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, acetone, tetrahydrofuran or a mixed solvent composed of the above solvents; preferably, the solvent used is selected from tetrahydrofuran; the reaction temperature is -5°C to 25°C; preferably, the reaction temperature is 0°C.

[0126] Compound IE is prepared by reacting compound j with a demethylation agent, wherein the demethylation agent is selected from lithium chloride, aluminum chloride, boron tribromide, hydrobromic acid or hydroiodic acid; preferably, the demethylation agent is selected from lithium chloride; the solvent is selected from N,N-dimethylformamide, N,N-diethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, isopropanol, ethanol or a mixed solvent composed of the above solvents; preferably, the solvent is selected from N,N-dimethylformamide; the reaction temperature is 100°C to 140°C; preferably, the reaction temperature is 130°C.

[0127] Compounds IA, IB, IC, ID and IE prepared by the above method are salified with corresponding acids to obtain pharmaceutically acceptable salts of the above URAT1 inhibitors.

[0128] The technical solution of the present invention is further described below in conjunction with embodiments.

[0129] Example 1: Synthesis of (3,5-difluoro-4-hydroxyphenyl)(1-oxospiro[benzo[b][1,4]thiazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-A1)

[0130] Synthesis of (3,5-difluoro-4-methoxyphenyl)(spiro[benzo[b][1,4]thiazin-2,1'-cyclopropane]-4(3H)-yl)methanone (IV-1)

[0131] 3,5-difluoro-4-methoxybenzoic acid (III-2, 500 mg, 2.37 mmol) and thionyl chloride (25 mL) were added to a 100 mL three-necked flask, heated to 70 ° C, stirred for reaction for 3 hours, and the solvent was evaporated under reduced pressure. After the crude product was dissolved in anhydrous THF (20 mL), it was cooled to 0 ° C. Under nitrogen protection, a mixed solution of 3,4-dihydrospiro[benzo[b][1,4]thiazine-2,1'-cyclopropane] (II-1, 467 mg, 2.48 mmol) dissolved in anhydrous THF (15 mL) was slowly added dropwise. After the dropwise addition, the mixture was reacted at 0 ° C for 1 hour, and then moved to room temperature for reaction for 6 hours. TLC monitoring (petroleum ether: ethyl acetate = 20:1) showed that the reaction was basically complete. The solvent was evaporated under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 100:1~30:1) to obtain 600 mg of white solid IV-1, with a yield of 61.2%. MS (ESI (+) 70V) m / z [M+H] + :348.08.

[0132] Synthesis of (3,5-difluoro-4-methoxyphenyl)(1-oxospiro[benzo[b][1,4]thiazin-2,1'-cyclopropane]-4(3H)-yl)methanone (V-1)

[0133] IV-1 (150 mg, 0.43 mmol) and dichloromethane (10 mL) were added to a 50 mL three-necked flask, stirred and dissolved, cooled to 0 ° C, and a solution of m-chloroperbenzoic acid (74.2 mg, 0.43 mmol) in dichloromethane (5 mL) was slowly added dropwise. The reaction was completed after about 0.5 hours of dropping. TLC monitoring (petroleum ether: ethyl acetate = 1:1) showed that the reaction was basically complete. Saturated sodium sulfite aqueous solution (50 mL) was added to quench the reaction, and the dichloromethane layer was separated. The water layer was extracted with dichloromethane (20 mL × 3), and the organic phases were combined, washed with saturated sodium chloride solution (15 mL × 3), and dried over anhydrous sodium sulfate; filtered, the filtrate was concentrated under reduced pressure to remove the solvent, and the crude product was separated and purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 5:1 to 1:2) to obtain 130 mg of off-white solid V-1, with a yield of 82.9%. MS (ESI (+) 70V) m / z [M + H] + :364.38.

[0134] Synthesis of (3,5-difluoro-4-hydroxyphenyl)(1-oxospiro[benzo[b][1,4]thiazin-2,1'-cyclopropane]-4(3H)-yl)methanone (I-A1)

[0135] To a 25 mL eggplant-shaped flask, add intermediate V-1 (110 mg, 0.30 mmol) and DMF (6 mL). After fully dissolved, add lithium chloride (103 mg, 2.42 mmol). Protect with nitrogen and heat to 130 ° C for 8 hours. TLC monitoring (petroleum ether: ethyl acetate = 1:2) shows that the reaction is basically complete. Cool to room temperature, pour the reaction solution into ice water (5 mL), add 2 mol / L hydrochloric acid to adjust the pH to 3-5, extract with ethyl acetate (40 mL × 3), combine the organic phases, wash with saturated sodium chloride solution (20 mL × 2), and dry over anhydrous sodium sulfate; filter with suction, concentrate the filtrate under reduced pressure to remove the solvent, and purify the crude product by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 8: 1 to 1: 1) to obtain 52 mg of white solid I-A1 with a yield of 49.2%. 1 H NMR(400MHz, DMSO-d6)δ(ppm):10.93(s,1H),7.71(dd,J=8.0,4.0Hz,1H),7.39–7.31(m,2H),7.05(d,J=1.6Hz,1H),7.04(d,J=1.7Hz,1H),7.01(dd, J=8.0,4.0Hz,1H),4.16(d,J=16.0Hz,1H),3.93(d,J=16.0Hz,1H),1.30-1 .24(m,1H),1.19-1.13(m,1H),1.02-0.91(m,2H).MS(ESI(+)70V)m / z[M+H] + :350.35.

[0136] Example 2: Synthesis of (3,5-dichloro-4-hydroxyphenyl)(1-oxospiro[benzo[b][1,4]thiazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-A2)

[0137] Synthesis of (3,5-dichloro-4-methoxyphenyl)(spiro[benzo[b][1,4]thiazin-2,1'-cyclopropane]-4(3H)-yl)methanone (IV-2)

[0138] Using intermediate II-1 (400 mg, 2.26 mmol) and 3,5-dichloro-4-methoxybenzoic acid (III-3, 499 mg, 2.26 mmol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 670 mg of off-white solid IV-2 with a yield of 78.1%. MS (ESI (+) 70V) m / z [M+H] + :380.02.

[0139] Synthesis of (3,5-dichloro-4-methoxyphenyl)(1-oxospiro[benzo[b][1,4]thiazin-2,1'-cyclopropane]-4(3H)-yl)methanone (V-2)

[0140] Using intermediate IV-2 (118 mg, 0.31 mmol) as raw material, refer to the preparation method of intermediate V-1 to obtain 100 mg of off-white solid V-2 with a yield of 81.3%. MS (ESI (+) 70V) m / z [M+H] + :396.01.

[0141] Synthesis of (3,5-dichloro-4-hydroxyphenyl)(1-oxospiro[benzo[b][1,4]thiazin-2,1'-cyclopropane]-4(3H)-yl)methanone (I-A2)

[0142] Using intermediate V-2 (82 mg, 0.21 mmol) as raw material and referring to the preparation method of compound I-A1, 50 mg of off-white solid I-A2 was obtained with a yield of 63.2%. 1 H NMR(300MHz, DMSO-d6)δ(ppm):7.72(d,J=6.1Hz,1H),7.40-7.32(m,4H),7.04(d,J=7.3Hz,1H),4.18(d,J=13.6H z,1H),3.92(d,J=13.7Hz,1H),1.32-1.24(m,1H),1.17-1.13(m,1H),0.99-0.93(m,2H).MS(ESI(+)70V)m / z[M+H] + :381.99.

[0143] Example 3: Synthesis of (3,5-dibromo-4-hydroxyphenyl)(1-oxospiro[benzo[b][1,4]thiazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-A3)

[0144] Synthesis of (3,5-dibromo-4-methoxyphenyl)(spiro[benzo[b][1,4]thiazin-2,1'-cyclopropane]-4(3H)-yl)methanone (IV-3)

[0145] Using intermediate II-1 (400 mg, 2.26 mmol) and 3,5-dibromo-4-methoxybenzoic acid (III-5, 769 mg, 2.48 mmol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 450 mg of light yellow oil IV-3 with a yield of 42.5%. MS (ESI (+) 70V) m / z [M+H] + :467.92.

[0146] Synthesis of (3,5-dibromo-4-methoxyphenyl)(1-oxospiro[benzo[b][1,4]thiazin-2,1'-cyclopropane]-4(3H)-yl)methanone (V-3)

[0147] Using intermediate IV-3 (100 mg, 0.21 mmol) as raw material, refer to the preparation method of intermediate V-1 to obtain 100 mg of off-white solid V-3 with a yield of 96.7%. MS (ESI (+) 70V) m / z [M+H] + :483.91.

[0148] Synthesis of (3,5-dibromo-4-hydroxyphenyl)(1-oxospiro[benzo[b][1,4]thiazin-2,1'-cyclopropane]-4(3H)-yl)methanone (I-A3)

[0149] Using intermediate V-3 (100 mg, 0.21 mmol) as raw material and referring to the preparation method of compound I-A1, 90 mg of off-white solid I-A3 was obtained with a yield of 92.7%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 7.73 (dd, J=7.3, 1.9Hz, 1H), 7.46 (s, 2H), 7.42–7.31 (m, 2H), 7.05 (dd, J=7.8, 1.5Hz, 1H), 4.17 (d,J=13.6Hz,1H),3.94(d,J=13.6Hz,1H),1.35–1.24(m,1H),1.23–1.12(m,1H),1.07–0.89(m,2H).MS(ESI(+)70V)m / z[M+H] + :469.90.

[0150] Example 4: Synthesis of (3,5-dichloro-4-hydroxyphenyl)(1,1-dioxospiro[benzo[b][1,4]thiazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-B1)

[0151] Synthesis of (3,5-dichloro-4-methoxyphenyl)(1,1-dioxospiro[benzo[b][1,4]thiazin-2,1'-cyclopropane]-4(3H)-yl)methanone (VI-1)

[0152] IV-2 (124 mg, 0.33 mmol) and dichloromethane (10 mL) were added to a 50 mL three-necked flask, stirred to dissolve, cooled to 0 ° C, and a solution of m-chloroperbenzoic acid (142.4 mg, 0.83 mmol) in dichloromethane (5 mL) was slowly added dropwise. The dropwise addition was completed in about 0.5 hours. TLC monitoring (petroleum ether: ethyl acetate = 2: 1) showed that the reaction was basically complete. A saturated aqueous sodium sulfite solution (25 mL) was added to quench the reaction, and the dichloromethane layer was separated. The aqueous layer was extracted with dichloromethane (15 mL × 3), the organic phases were combined, washed with a saturated aqueous sodium chloride solution (15 mL × 3), and dried over anhydrous sodium sulfate; filtered, the filtrate was concentrated under reduced pressure to remove the solvent, and the crude product was separated and purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 15: 1 to 3: 1) to obtain 110 mg of off-white solid VI-1, with a yield of 81.8%. MS (ESI (+) 70V) m / z [M+H] + :412.01.

[0153] Synthesis of (3,5-dichloro-4-hydroxyphenyl)(1,1-dioxospiro[benzo[b][1,4]thiazin-2,1'-cyclopropane]-4(3H)-yl)methanone (I-B1)

[0154] Using intermediate VI-1 (80 mg, 0.19 mmol) as raw material and referring to the preparation method of compound I-A1, 50 mg of off-white solid I-B1 was obtained with a yield of 64.7%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 11.00 (s, 1H), 7.85 (dd, J = 7.7, 1.8Hz, 1H), 7.54–7.36 (m, 2H), 7.33 (s, 2 H),7.16(d,J=8.0Hz,1H),4.29(s,2H),1.41-1.37(m,2H),1.29–1.20(m,2H).MS(ESI(+)70V)m / z[M+H] + :397.99.

[0155] Example 5: Synthesis of (3,5-dibromo-4-hydroxyphenyl)(1,1-dioxospiro[benzo[b][1,4]thiazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-B2)

[0156] Synthesis of (3,5-dibromo-4-methoxyphenyl)(1,1-dioxospiro[benzo[b][1,4]thiazin-2,1'-cyclopropane]-4(3H)-yl)methanone (VI-2)

[0157] Using intermediate IV-3 (120 mg, 0.26 mmol) as raw material, refer to the preparation method of intermediate VI-1 to obtain 120 mg of off-white solid VI-2 with a yield of 93.6%. MS (ESI (+) 70V) m / z [M+H] + :499.91.

[0158] Synthesis of (3,5-dibromo-4-hydroxyphenyl)(1,1-dioxospiro[benzo[b][1,4]thiazin-2,1'-cyclopropane]-4(3H)-yl)methanone (I-B2)

[0159] Using intermediate VI-2 (120 mg, 0.24 mmol) as raw material and referring to the preparation method of compound I-A1, 110 mg of off-white solid I-B2 was obtained with a yield of 94.3%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 7.80 (dd, J=7.8, 1.4Hz, 1H), 7.49–7.41 (m, 1H), 7.39 (s, 2H), 7.36–7.29 (m,1H),7.13–7.04(m,1H),4.25(s,2H),1.42–1.30(m,2H),1.30–1.19(m,2H).MS(ESI(+)70V)m / z[M+H] + :485.89.

[0160] Example 6: (3,5-dichloro-4-hydroxyphenyl)(1-imino-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (I-C1)

[0161] Synthesis of (3,5-dichloro-4-methoxyphenyl)(2,3-dihydro-4H-benzo[b][1,4]thiazin-4-yl)methanone (VIII-1)

[0162] Using 3,4-dihydro-2H-benzo[b][1,4]thiazine (VII-1, 2.0 g, 0.01 mol) and intermediate III-3 (3.51 g, 0.02 mol) as raw materials, referring to the preparation method of intermediate IV-1, 3.19 g of off-white solid VIII-1 was obtained, with a yield of 68.1%. MS (ESI (+) 70V) m / z [M+H] + :354.00

[0163] (3,5-dichloro-4-methoxyphenyl)(1-imino-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (IX-1)

[0164] Add intermediate VIII-1 (1.0 g, 2.83 mmol) and methanol (5 mL) to a 15 mL pressure bottle. After fully dissolving, add iodobenzene diacetic acid (2.73 g, 8.5 mmol) and ammonium carbamate (1.1 g, 14.2 mmol). React at 25 ° C for 12 hours. TLC monitoring (petroleum ether: ethyl acetate = 5:1) shows that the reaction is basically complete. Concentrate under reduced pressure to remove the solvent, and the crude product is separated and purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 2:1 to 1:1) to obtain 0.93 g of off-white solid IX-1, with a yield of 85.5%. MS (ESI (+) 70V) m / z [M + H] + :385.01.

[0165] (3,5-dichloro-4-hydroxyphenyl)(1-imino-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (I-C1)

[0166] Using intermediate IX-1 (50.0 mg, 0.13 mmol) as raw material and referring to the preparation method of compound I-A1, 30.8 mg of off-white solid I-C1 was obtained with a yield of 63.9%. 1 H NMR(300MHz,DMSO-d6)δ(ppm):8.32(s,1H),7.94–7.82(m,1H),7.40–7.29(m,4H),7.05– 6.90(m,1H),4.90(s,1H),4.36-4.18(m,2H),3.78-3.62(m,2H).MS(ESI(+)70V)m / z[M+H] + :370.99.

[0167] Example 7: (3,5-dibromo-4-hydroxyphenyl)(1-imino-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (I-C2)

[0168] Synthesis of (3,5-dibromo-4-methoxyphenyl)(2,3-dihydro-4H-benzo[b][1,4]thiazin-4-yl)methanone (VIII-2)

[0169] Using intermediate VII-1 (500 mg, 3.31 mmol) and III-5 (1.23 g, 3.39 mmol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 850 mg of off-white solid VIII-2 with a yield of 58.0%. MS (ESI (+) 70V) m / z [M+H] + :441.90

[0170] (3,5-dibromo-4-methoxyphenyl)(1-imino-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (IX-2)

[0171] Using intermediate VIII-2 (300 mg, 0.68 mmol) as raw material, referring to the preparation method of compound IX-1, 250 mg of off-white solid IX-2 was obtained with a yield of 77.9%. MS (ESI (+) 70V) m / z [M+H] + :472.91.

[0172] (3,5-dibromo-4-hydroxyphenyl)(1-imino-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (I-C2)

[0173] Using intermediate IX-2 (200 mg, 0.42 mmol) as raw material and referring to the preparation method of compound I-A1, 126 mg of off-white solid I-C2 was obtained with a yield of 64.9%. 1 H NMR(300MHz,DMSO-d6)δ(ppm):10.59(s,1H),7.93–7.83(m,1H),7.51(s,2H),7.38-7.30(m,2H),7. 06–6.91(m,1H),4.97(s,1H),4.26(q,J=6.3Hz,2H),3.70(q,J=6.0Hz,2H).MS(ESI(+)70V)m / z[M+H] + :458.89.

[0174] Example 8: (3,5-difluoro-4-hydroxyphenyl)(1-imino-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (I-C3)

[0175] Synthesis of (3,5-difluoro-4-methoxyphenyl)(2,3-dihydro-4H-benzo[b][1,4]thiazin-4-yl)methanone (VIII-3)

[0176] Using intermediate VII-1 (1.0 g, 6.6 mmol) and III-2 (1.5 g, 8.0 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 1.86 g of off-white solid VIII-3 was obtained with a yield of 87.5%. MS (ESI (+) 70V) m / z [M+H] + :322.06.

[0177] (3,5-difluoro-4-methoxyphenyl)(1-imino-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (IX-3)

[0178] Using intermediate VIII-3 (500 mg, 1.6 mmol) as raw material, referring to the preparation method of compound IX-1, 347.7 mg of off-white solid IX-3 was obtained, with a yield of 63.4%. MS (ESI (+) 70V) m / z [M+H] + :353.07.

[0179] (3,5-difluoro-4-hydroxyphenyl)(1-imino-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (I-C3)

[0180] Using intermediate IX-3 (246 mg, 0.70 mmol) as raw material and referring to the preparation method of compound I-A1, 97 mg of off-white solid I-C3 was obtained with a yield of 41.1%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 10.91 (s, 1H), 7.86 (dd, J=7.5, 2.7Hz, 1H), 7.35-7.31 (m, 2H), 7.05 (dd, J=6.9, 1.8Hz, 2H), 6.93 (dd, J =6.9,2.7Hz,1H),4.97(s,1H),4.37-4.28(m,1H),4.22-4.13(m,1H),3.76-3.70(m,1H),3.68-3.61(m,1H).MS(ESI(+)70V)m / z[M+H] + :339.05.

[0181] Example 9: (3-Fluoro-4-hydroxyphenyl)(1-imino-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (I-C4)

[0182] Synthesis of (2,3-dihydro-4H-benzo[b][1,4]thiazin-4-yl)(3-fluoro-4-methoxyphenyl)methanone (VIII-4)

[0183] Using intermediate VII-1 (1.48 g, 0.01 mol) and 3-fluoro-4-methoxybenzoic acid (III-1, 1.9 g, 0.01 mol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 3.15 g of off-white solid VIII-4, with a yield of 87.3%. MS (ESI (+) 70V) m / z [M+H] + :304.07.

[0184] (3-Fluoro-4-methoxyphenyl)(1-imino-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (IX-4)

[0185] Using intermediate VIII-4 (500 mg, 1.66 mmol) as raw material, referring to the preparation method of compound IX-1, 472.8 mg of off-white solid IX-4 was obtained, with a yield of 85.8%. MS (ESI (+) 70V) m / z [M+H] + :335.08.

[0186] (3-Fluoro-4-hydroxyphenyl)(1-imino-1-oxo-2,3-dihydro-1λ 4 -benzo[b][1,4]thiazin-4(1H)-yl)

[0187] Synthesis of Ketone (I-C4)

[0188] Using intermediate IX-4 (200 mg, 0.60 mmol) as raw material and referring to the preparation method of compound I-A1, 89.4 mg of off-white solid I-C4 was obtained with a yield of 46.7%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 10.52 (s, 1H), 7.91-7.81 (m, 1H), 7.35-7.25 (m, 2H), 7.18-7.14 (m, 1H), 7.03 (dd, J=8.3, 2.0 Hz,1H),6.88-6.82(m,2H),4.93(s,1H),4.38-4.27(m,1H),4.23-4.14(m,1H),3.72-3.58(m,2H).MS(ESI(+)70V)m / z[M+H] + :321.06.

[0189] Example 10: (3,5-dichloro-4-hydroxyphenyl)(7-bromo-1-imino-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (I-C5)

[0190] Synthesis of (3,5-dichloro-4-methoxyphenyl)(7-bromo-2,3-dihydro-4H-benzo[b][1,4]thiazin-4-yl)methanone (VIII-5)

[0191] Using 7-bromo-3,4-dihydro-2H-benzo[b][1,4]thiazine (VII-2, 500 mg, 2.17 mmol) and intermediate III-3 (576 mg, 2.61 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 720 mg of off-white solid VIII-5 was obtained with a yield of 76.5%. MS (ESI (+) 70V) m / z [M+H] + :431.91.

[0192] (3,5-dichloro-4-methoxyphenyl)(7-bromo-1-imino-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-Benzo[b][1,4]thiazin-4(1H)-yl)methanone (IX-5)

[0193] Using intermediate VIII-5 (300 mg, 0.69 mmol) as raw material, referring to the preparation method of compound IX-1, 210 mg of off-white solid IX-5 was obtained with a yield of 65.3%. MS (ESI (+) 70V) m / z [M+H] + :462.92.

[0194] (3,5-dichloro-4-hydroxyphenyl)(7-bromo-1-imino-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (I-C5)

[0195] Using intermediate IX-5 (200 mg, 0.43 mmol) as raw material and referring to the preparation method of compound I-A1, 160 mg of off-white solid I-C5 was obtained with a yield of 82.5%. 1 H NMR(300MHz,DMSO-d6)δ(ppm):8.02(d,J=2.3Hz,1H),7.54(dd,J=8.7,2.4Hz,1H),7.39(s,2H),7 .00(d,J=8.7Hz,1H),5.18(s,1H),4.39–4.14(m,2H),3.82–3.61(m,2H).MS(ESI(+)70V)m / z[M+H] + :448.91.

[0196] Example 11: (4-Hydroxy-3,5-diiodophenyl) (1-imino-1-oxo-2,3-dihydro-1λ 4Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (I-C6)

[0197] Synthesis of (3,5-diiodo-4-methoxyphenyl)(2,3-dihydro-4H-benzo[b][1,4]thiazin-4-yl)methanone (VIII-6)

[0198] Using intermediate VII-1 (200 mg, 1.32 mmol) and 3,5-diiodo-4-methoxybenzoic acid (III-6, 589.7 mg, 1.46 mmol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 327.8 mg of off-white solid VIII-6, with a yield of 46.1%. MS (ESI (+) 70V) m / z [M+H] + :537.88.

[0199] (3,5-diiodo-4-methoxyphenyl)(1-imino-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (IX-6)

[0200] Using intermediate VIII-6 (200 mg, 0.37 mmol) as raw material, referring to the preparation method of compound IX-1, 192.3 mg of off-white solid IX-6 was obtained, with a yield of 90.9%. MS (ESI (+) 70V) m / z [M+H] + :568.88.

[0201] (4-Hydroxy-3,5-diiodophenyl)(1-imino-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (I-C6)

[0202] Using intermediate IX-6 (92.0 mg, 0.17 mmol) as raw material and referring to the preparation method of compound I-A1, 56.2 mg of off-white solid I-C6 was obtained with a yield of 62.6%. 1 H NMR(300MHz,DMSO-d6)δ(ppm):7.91-7.84(m,1H),7.70(s,2H),7.38-7.29(m,2H),6.97-6.9 3(m,1H),4.90(s,1H),4.25(t,J=6.3Hz,2H),3.68(t,J=6.1Hz,2H).MS(ESI(+)70V)m / z[M+H] + :554.87.

[0203] Example 12: 5-(7-bromo-1-imino-1-oxo-1,2,3,4-tetrahydro-1λ4 Synthesis of 2-Benzo[b][1,4]thiazine-4-carbonyl)-2-hydroxy-3-iodobenzonitrile (I-C7)

[0204] Synthesis of 4-(7-bromo-3,4-dihydro-2H-benzo[b][1,4]thiazine-4-carbonyl)-3-iodo-2-methoxybenzonitrile (VIII-7)

[0205] Using intermediate VII-2 (300 mg, 1.30 mmol) and 3-cyano-5-iodo-4-methoxybenzoic acid (III-9, 434.6 mg, 1.43 mmol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 500 mg of off-white solid VIII-7 with a yield of 74.5%. MS (ESI (+) 70V) m / z [M+H] + :514.88.

[0206] 5-(7-bromo-1-imino-1-oxo-1,2,3,4-tetrahydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazine-4-carbonyl)-3-iodo-2-methoxybenzonitrile (IX-7)

[0207] Using intermediate VIII-7 (500 mg, 0.97 mmol) as raw material, referring to the preparation method of compound IX-1, 100 mg of off-white solid IX-7 was obtained with a yield of 18.9%. MS (ESI (+) 70V) m / z [M+H] + :545.89.

[0208] 5-(7-bromo-1-imino-1-oxo-1,2,3,4-tetrahydro-1λ 4 Synthesis of 2-Benzo[b][1,4]thiazine-4-carbonyl)-2-hydroxy-3-iodobenzonitrile (I-C7)

[0209] Using intermediate IX-7 (90 mg, 0.17 mmol) as raw material and referring to the preparation method of compound I-A1, 78.2 mg of off-white solid I-C7 was obtained with a yield of 89.2%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 8.00 (d, J = 2.4Hz, 1H), 7.77 (d, J = 2.5Hz, 1H), 7.51 (dd, J = 8.9, 2.4Hz, 1H), 7 .28(d,J=2.5Hz,1H),6.93(d,J=8.9Hz,1H),4.39–4.11(m,2H),3.72-3.57(m,2H).MS(ESI(+)70V)m / z[M+H] + :531.87.

[0210] Example 13: (3,5-dichloro-4-hydroxyphenyl)(1-imino-7-methyl-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (I-C8)

[0211] Synthesis of (3,5-dichloro-4-methoxyphenyl)(7-methyl-2,3-dihydro-4H-benzo[b][1,4]thiazin-4-yl)methanone (VIII-8)

[0212] Using 7-methyl-3,4-dihydro-2H-benzo[b][1,4]thiazine (VII-3, 200 mg, 1.2 mmol) and intermediate III-3 (294 mg, 1.33 mmol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 300 mg of off-white solid VIII-8 with a yield of 67.1%. MS (ESI (+) 70V) m / z [M+H] + :368.02.

[0213] (3,5-dichloro-4-methoxyphenyl)(1-imino-7-methyl-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (IX-8)

[0214] Using intermediate VIII-8 (200 mg, 0.54 mmol) as raw material, referring to the preparation method of compound IX-1, 175 mg of off-white solid IX-8 was obtained with a yield of 80.7%. MS (ESI (+) 70V) m / z [M+H] + :399.03.

[0215] (3,5-dichloro-4-hydroxyphenyl)(1-imino-7-methyl-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (I-C8)

[0216] Using intermediate IX-8 (140 mg, 0.35 mmol) as raw material and referring to the preparation method of compound I-A1, 66 mg of off-white solid I-C8 was obtained with a yield of 48.9%. 1H NMR (300MHz, DMSO-d6) δ (ppm): 10.84 (s, 1H), 7.68 (s, 1H), 7.34 (s, 2H), 7.14 (dd, J = 8.4, 2.1Hz, 1H), 6.85 ( d,J=8.1Hz,1H),4.91(s,1H),4.32-4.14(m,2H),3.75-3.59(m,2H),2.31(s,3H).MS(ESI(+)70V)m / z[M+H] + :385.01.

[0217] Example 14: (3,5-dibromo-4-hydroxyphenyl)(1-imino-7-methyl-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (I-C9)

[0218] Synthesis of (3,5-dibromo-4-methoxyphenyl)(7-methyl-2,3-dihydro-4H-benzo[b][1,4]thiazin-4-yl)methanone (VIII-9)

[0219] Using intermediate VII-3 (120 mg, 0.73 mmol) and intermediate III-5 (248 mg, 0.80 mmol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 200 mg of off-white solid VIII-9 with a yield of 60.2%. MS (ESI (+) 70V) m / z [M+H] + :455.92.

[0220] (3,5-dibromo-4-methoxyphenyl)(1-imino-7-methyl-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (IX-9)

[0221] Using intermediate VIII-9 (180 mg, 0.39 mmol) as raw material, referring to the preparation method of compound IX-1, 140 mg of off-white solid IX-9 was obtained, with a yield of 72.8%. MS (ESI (+) 70V) m / z [M+H] + :486.92.

[0222] (3,5-dibromo-4-hydroxyphenyl)(1-imino-7-methyl-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (I-C9)

[0223] Using intermediate IX-9 (120 mg, 0.25 mmol) as raw material and referring to the preparation method of compound I-A1, 64 mg of off-white solid I-C9 was obtained with a yield of 54.9%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 10.54 (s, 1H), 7.68 (s, 1H), 7.50 (s, 2H), 7.15 (dd, J = 8.4, 2.1Hz, 1H), 6.85 ( d,J=8.1Hz,1H),4.86(s,1H),4.31-4.14(m,2H),3.69-3.63(m,2H),2.31(s,3H).MS(ESI(+)70V)m / z[M+H] + :472.91.

[0224] Example 15: (3,5-difluoro-4-hydroxyphenyl)(1-imino-7-methyl-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (I-C10)

[0225] Synthesis of (3,5-difluoro-4-methoxyphenyl)(7-methyl-2,3-dihydro-4H-benzo[b][1,4]thiazin-4-yl)methanone (VIII-10)

[0226] Using intermediate VII-3 (150 mg, 0.91 mmol) and intermediate III-2 (188 mg, 1.0 mmol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 242 mg of yellow solid VIII-10, with a yield of 79.5%. MS (ESI (+) 70V) m / z [M+H] + :336.08.

[0227] (3,5-difluoro-4-methoxyphenyl)(1-imino-7-methyl-1-oxo-2,3-dihydro-1λ 4 Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (IX-10)

[0228] Using intermediate VIII-10 (220 mg, 0.66 mmol) as raw material, referring to the preparation method of compound IX-1, 190 mg of off-white solid IX-10 was obtained with a yield of 79.1%. MS (ESI (+) 70V) m / z [M+H] + :367.08.

[0229] (3,5-difluoro-4-hydroxyphenyl)(1-imino-7-methyl-1-oxo-2,3-dihydro-1λ 4Synthesis of 4-benzo[b][1,4]thiazin-4(1H)-yl)methanone (I-C10)

[0230] Using intermediate IX-10 (170 mg, 0.46 mmol) as raw material and referring to the preparation method of compound I-A1, 77 mg of off-white solid I-C10 was obtained with a yield of 50.0%. 1 H NMR (400MHz, DMSO-d6) δ (ppm): 10.86 (s, 1H), 7.68 (d, J = 2.0Hz, 1H), 7.13 (dd, J = 8.4, 2.0Hz, 1H), 7.04 (dd, J = 6.8, 1.6Hz, 2H), 6.80 (d, J = 8 .4Hz,1H),4.88(s,1H),4.34-4.27(m,1H),4.18-4.11(m,1H),3.74-3.68(m,1H),3.64-3.57(m,1H),2.31(s,3H).MS(ESI(+)70V)m / z[M+H] + :353.07.

[0231] Example 16: Synthesis of (3,5-dichloro-4-hydroxyphenyl)(spiro[benzo[b][1,4]thiazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-D1)

[0232] Using intermediate IV-2 (100 mg, 0.26 mmol) as raw material and referring to the preparation method of compound I-A1, 87 mg of off-white solid I-D1 was obtained with a yield of 90.3%. 1 H NMR(300MHz,DMSO-d6)δ(ppm):10.85(s,1H),7.43–7.05(m,4H),7.02–6.70(m,2 H),3.93(s,2H),1.10-1.06(m,2H),0.98-0.82(m,2H).MS(ESI(+)70V)m / z[M+H] + :366.00.

[0233] Example 17: Synthesis of (3,5-dibromo-4-hydroxyphenyl)(spiro[benzo[b][1,4]thiazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-D2)

[0234] Using intermediate IV-3 (100 mg, 0.21 mmol) as raw material and referring to the preparation method of compound I-A1, 55 mg of off-white solid I-D2 was obtained with a yield of 56.7%. 1H NMR (400MHz, DMSO-d6) δ (ppm): 7.35-7.27 (m, 2H), 7.26-7.16 (m, 1H), 7.08 (td, J = 7.6, 1.6Hz, 1H), 6.93 (td, J = 7. 7,1.5Hz,1H),6.82(d,J=8.1Hz,1H),3.89(s,2H),1.08-0.96(m,2H),0.91-0.84(m,2H).MS(ESI(+)70V)m / z[M+H] + :453.90.

[0235] Example 18: Synthesis of (3,5-difluoro-4-hydroxyphenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E1)

[0236] Synthesis of (3,5-difluoro-4-methoxyphenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (XI-1)

[0237] Using 3,4-dihydrospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane] (X-1, 150.0 mg, 0.93 mmol) and intermediate III-2 (210.0 mg, 1.12 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 266.91 mg of off-white solid XI-1 was obtained, with a yield of 86.6%. MS (ESI (+) 70V) m / z [M+H] + :332.10.

[0238] Synthesis of (3,5-difluoro-4-hydroxyphenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E1)

[0239] Using intermediate XI-1 (130.0 mg, 0.39 mmol) as raw material and referring to the preparation method of compound I-A1, 96.8 mg of off-white solid I-E1 was obtained with a yield of 77.8%. 1 H NMR (400MHz, DMSO-d6) δ (ppm): 10.89 (s, 1H), 7.35 (s, 1H), 7.29–7.17 (m, 2H), 7.08–6.98 (m, 1H), 6. 95–6.75(m,2H),3.85(s,2H),0.97(t,J=6.4Hz,2H),0.72(t,J=6.4Hz,2H).MS(ESI(+)70V)m / z[M+H] + :318.09.

[0240] Example 19: Synthesis of (3,5-dichloro-4-hydroxyphenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E2)

[0241] Synthesis of (3,5-dichloro-4-methoxyphenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (XI-2)

[0242] Using intermediate X-1 (100.0 mg, 0.62 mmol) and III-3 (150.8 mg, 0.68 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 126.4 mg of off-white solid XI-2 was obtained, with a yield of 55.9%. MS (ESI (+) 70V) m / z [M+H] + :364.04.

[0243] Synthesis of (3,5-dichloro-4-hydroxyphenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E2)

[0244] Using intermediate XI-2 (85.0 mg, 0.23 mmol) as raw material and referring to the preparation method of compound I-A1, 58.9 mg of off-white solid I-E2 was obtained with a yield of 72.1%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 10.85 (s, 1H), 7.51 (s, 2H), 7.35 (d, J = 6.7Hz, 1H), 7.04 (t, J = 7.3Hz, 1H) ,6.97–6.71(m,2H),3.86(s,2H),0.96(t,J=6.2Hz,2H),0.75(t,J=6.2Hz,2H).MS(ESI(+)70V)m / z[M+H] + :350.03.

[0245] Example 20: Synthesis of (3,5-dibromo-4-hydroxyphenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E3)

[0246] Synthesis of (3,5-dibromo-4-methoxyphenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (XI-3)

[0247] Using intermediate X-1 (150.0 mg, 0.93 mmol) and intermediate III-5 (346.1 mg, 1.12 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 287.9 ​​mg of off-white solid XI-3 was obtained, with a yield of 68.3%. MS (ESI (+) 70V) m / z [M+H] + :451.94.

[0248] Synthesis of (3,5-dibromo-4-hydroxyphenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E3)

[0249] Using intermediate XI-3 (170.0 mg, 0.38 mmol) as raw material and referring to the preparation method of compound I-A1, 108.3 mg of off-white solid I-E3 was obtained with a yield of 65.7%. 1 H NMR (300MHz, Chloroform-d) δ (ppm): 7.61 (s, 2H), 7.06-7.00 (m, 1H), 6.88 (dd, J = 8.3, 1.5Hz, 1H), 6.81–6. 68(m,1H),6.28(s,1H),3.91(s,2H),1.14(t,J=6.6Hz,2H),0.76(t,J=6.6Hz,2H).MS(ESI(+)70V)m / z[M+H] + :437.93.

[0250] Example 21: Synthesis of 5-(3,4-dihydrospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4-carbonyl)-2-hydroxy-3-iodobenzonitrile (I-E4)

[0251] Synthesis of 5-(3,4-dihydrospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4-carbonyl)-3-iodo-2-methoxybenzonitrile (XI-4)

[0252] Using intermediate X-1 (150 mg, 0.93 mmol) and intermediate III-9 (338.4 mg, 1.12 mmol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 240.7 mg off-white solid XI-4, with a yield of 58.0%. MS (ESI (+) 70V) m / z [M+H] + :447.01.

[0253] Synthesis of 5-(3,4-dihydrospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4-carbonyl)-2-hydroxy-3-iodobenzonitrile (I-E4)

[0254] Using intermediate XI-4 (118.0 mg, 0.93 mmol) as raw material and referring to the preparation method of compound I-A1, 106.5 mg of off-white solid I-E4 was obtained with a yield of 61.1%. 1 H NMR(400MHz, DMSO-d6)δ(ppm):8.01(d,J=2.2Hz,1H),7.65(d,J=2.2Hz,1H),7.30(d,J=8.2Hz,1H),7.07–6.95 (m,1H),6.92–6.76(m,2H),3.84(s,2H),0.95(t,J=6.4Hz,2H),0.73(t,J=6.4Hz,2H).MS(ESI(+)70V)m / z[M+H] + :433.00.

[0255] Example 22: Synthesis of (4-hydroxy-3,5-diiodophenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E5)

[0256] Synthesis of (3,5-diiodo-4-methoxyphenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (XI-5)

[0257] Using intermediate X-1 (150.0 mg, 0.93 mmol) and intermediate III-6 (451.0 mg, 1.12 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 286.8 mg of off-white solid XI-5 was obtained, with a yield of 56.3%. MS (ESI (+) 70V) m / z [M+H] + :547.91.

[0258] Synthesis of (4-hydroxy-3,5-diiodophenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E5)

[0259] Using intermediate XI-5 (177.0 mg, 0.32 mmol) as raw material and referring to the preparation method of compound I-A1, 109.2 mg of off-white solid I-E5 was obtained with a yield of 65.9%. 1 H NMR (400MHz, DMSO-d6) δ (ppm): 10.10 (s, 1H), 7.84 (s, 2H), 7.39–7.21 (m, 1H), 7.09–6.96 (m, 1H), 6. 89-6.82(m,2H),3.85(s,2H),0.96(t,J=6.2Hz,2H),0.75(t,J=6.2Hz,2H).MS(ESI(+)70V)m / z[M+H]+ :533.90.

[0260] Example 23: Synthesis of (3-fluoro-4-hydroxyphenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E6)

[0261] Synthesis of (3-fluoro-4-methoxyphenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (XI-6)

[0262] Using intermediate X-1 (100 mg, 0.62 mmol) and intermediate III-1 (106 mg, 0.62 mmol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 170 mg of off-white solid XI-6, with a yield of 87.5%. MS (ESI (+) 70V) m / z [M+H] + :314.11.

[0263] Synthesis of (3-fluoro-4-hydroxyphenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E6)

[0264] Using intermediate XI-6 (130 mg, 0.41 mmol) as raw material and referring to the preparation method of compound I-A1, 40 mg of off-white solid I-E6 was obtained with a yield of 32.2%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 10.54 (s, 1H), 7.32 (d, J = 11.6Hz, 1H), 7.28–7.12 (m, 2H), 7.05–6.93 (m, 2H) ),6.90–6.76(m,2H),3.84(s,2H),0.96(t,J=6.2Hz,2H),0.72(t,J=6.2Hz,2H).MS(ESI(+)70V)m / z[M+H] + :300.10.

[0265] Example 24: Synthesis of (3-chloro-4-hydroxy-5-nitrophenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E7)

[0266] Synthesis of (3-chloro-4-methoxy-5-nitrophenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (XI-7)

[0267] Using intermediate X-1 (486 mg, 3.59 mmol) and 3-chloro-4-methoxy-5-nitrobenzoic acid (III-7, 1.0 g, 4.32 mmol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 299.3 mg of yellow solid XI-7, with a yield of 26.5%. MS (ESI (+) 70V) m / z [M+H] + :375.07.

[0268] Synthesis of (3-chloro-4-hydroxy-5-nitrophenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E7)

[0269] Using intermediate XI-7 (0.9 g, 2.6 mmol) as raw material and referring to the preparation method of compound I-A1, 786.5 mg of off-white solid I-E7 was obtained with a yield of 90.8%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 7.74-7.67 (m, 4H), 7.21 (dd, J = 8.8, 2.4Hz, 1H), 6.85 (d, J = 8. 7Hz,1H),3.83(s,2H),0.93(t,J=6.2Hz,2H),0.73(t,J=6.2Hz,2H).MS(ESI(+)70V)m / z[M+H] + :361.05.

[0270] Example 25: Synthesis of (3-bromo-4-hydroxyphenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E8)

[0271] Synthesis of (3-bromo-4-methoxyphenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (XI-8)

[0272] Using intermediate X-1 (150 mg, 0.93 mmol) and 3-bromo-4-methoxybenzoic acid (III-4, 258 mg, 1.12 mmol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 120 mg of light yellow oil XI-8, with a yield of 34.5%. MS (ESI (+) 70V) m / z [M+H] + :374.03.

[0273] Synthesis of (3-bromo-4-hydroxyphenyl)(spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E8)

[0274] Using intermediate XI-8 (120 mg, 0.32 mmol) as raw material and referring to the preparation method of compound I-A1, 40 mg of off-white solid I-E8 was obtained with a yield of 34.6%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 10.94 (s, 1H), 7.64 (s, 1H), 7.35 (d, J = 8.5Hz, 1H), 7.29–7.14 (m, 1H), 7.07–6 .92(m,2H),6.92–6.73(m,2H),3.85(s,2H),0.98–0.93(m,2H),0.74–0.68(m,2H).MS(ESI(+)70V)m / z[M+H] + :360.02.

[0275] Example 26: Synthesis of 3-bromo-5-(3,4-dihydrospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4-carbonyl)-2-hydroxybenzonitrile (I-E9)

[0276] Synthesis of 1-bromo-5-(3,4-dihydrospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4-carbonyl)-2-methoxybenzonitrile (XI-9)

[0277] Using intermediate X-1 (150 mg, 0.93 mmol) and 3-bromo-4-methoxy-5-cyanobenzoic acid (III-8, 238 mg, 0.93 mmol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 236 mg of off-white solid XI-9, with a yield of 63.5%. MS (ESI (+) 70V) m / z [M+H] + :399.03.

[0278] Synthesis of 3-bromo-5-(3,4-dihydrospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4-carbonyl)-2-hydroxybenzonitrile (I-E9)

[0279] Using intermediate XI-9 (150 mg, 0.38 mmol) as raw material and referring to the preparation method of compound I-A1, 111 mg of off-white solid I-E9 was obtained with a yield of 76.7%. 1H NMR(300MHz, DMSO-d6)δ(ppm):7.97(d,J=2.1Hz,1H),7.84(d,J=2.0Hz,1H),7.42(s,1H),7.06(td,J=8.4,7.0,1 .6Hz,1H),6.94–6.81(m,2H),3.86(s,2H),0.96(t,J=6.2Hz,2H),0.74(t,J=6.2Hz,2H).MS(ESI(+)70V)m / z[M+H] + :385.01.

[0280] Example 27: Synthesis of (3,5-dichloro-4-hydroxyphenyl)(7-bromospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E10)

[0281] Synthesis of (3,5-dichloro-4-methoxyphenyl)(7-bromospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (XI-10)

[0282] Using 7-bromo-3,4-dihydrospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane] (X-2, 180 mg, 0.75 mmol) and intermediate III-3 (166 mg, 0.75 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 217.3 mg of off-white solid XI-10 was obtained, with a yield of 65.3%. MS (ESI (+) 70V) m / z [M+H] + :441.95.

[0283] Synthesis of (3,5-dichloro-4-hydroxyphenyl)(7-bromospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E10)

[0284] Using intermediate XI-10 (150 mg, 0.34 mmol) as raw material and referring to the preparation method of compound I-A1, 110 mg of off-white solid was obtained with a yield of 75.7%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 7.80–7.73 (m, 1H), 7.57 (s, 2H), 7.22 (dd, J = 8.8, 2.4Hz, 1H), 6.87 (d ,J=8.7Hz,1H),3.84(s,2H),0.94(t,J=6.2Hz,2H),0.73(t,J=6.2Hz,2H).MS(ESI(+)70V)m / z[M+H] + :427.94.

[0285] Example 28: Synthesis of (3,5-difluoro-4-hydroxyphenyl)(7-bromospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E11)

[0286] Synthesis of (3,5-difluoro-4-methoxyphenyl)(7-bromospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (XI-11)

[0287] Using intermediate X-2 (150 mg, 0.62 mmol) and intermediate III-2 (118 mg, 0.62 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 187 mg of off-white solid XI-11 was obtained, with a yield of 73.0%. MS (ESI (+) 70V) m / z [M+H] + :410.01.

[0288] Synthesis of (3,5-difluoro-4-hydroxyphenyl)(7-bromospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E11)

[0289] Using intermediate XI-11 (150 mg, 0.37 mmol) as raw material and referring to the preparation method of compound I-A1, 120 mg of off-white solid I-E10 was obtained with a yield of 82.8%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 7.89 (s, 2H), 7.72 (s, 1H), 7.22 (dd, J = 8.8, 2.4Hz, 1H), 6.87 (s, 1H) ,6.85(s,1H),3.83(s,2H),0.94(t,J=6.0Hz,2H),0.74(t,J=6.0Hz,2H).MS(ESI(+)70V)m / z[M+H] + :396.00.

[0290] Example 29: Synthesis of (3,5-difluoro-4-hydroxyphenyl)(spiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-yl)methanone (I-E12)

[0291] Synthesis of (3,5-difluoro-4-methoxyphenyl)(spiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-yl)methanone (XI-12)

[0292] Using 3',4'-dihydrospiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine] (X-3, 150 mg, 0.93 mmol) and intermediate III-2 (208 mg, 0.85 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 109.48 mg of off-white solid XI-12 was obtained, with a yield of 35.6%. MS (ESI (+) 70V) m / z [M+H] + :333.31.

[0293] Synthesis of (3,5-difluoro-4-hydroxyphenyl)(spiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-yl)methanone (I-E12)

[0294] Using intermediate XI-12 (70 mg, 0.21 mmol) as raw material and referring to the preparation method of compound I-A1, 39.45 mg of off-white solid I-E12 was obtained with a yield of 58.8%. 1 H NMR(400MHz,Chloroform-d)δ(ppm):8.68-8.57(m,1H),8.16-7.97(m,1H),8.07(s,1H),7.26(s,2H), 7.20-6.90(m,1H),3.91(s,2H),1.01(t,J=6.3Hz,2H),0.71(t,J=6.3Hz,2H).MS(ESI(+)70V)m / z[M+H] + :319.28.

[0295] Example 30: Synthesis of (3,5-dichloro-4-hydroxyphenyl)(spiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-yl)methanone (I-E13)

[0296] Synthesis of (3,5-dichloro-4-methoxyphenyl)(spiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-yl)methanone (XI-13)

[0297] Using intermediate X-3 (300 mg, 0.92 mmol) and intermediate III-3 (490 mg, 1.1 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 278.19 mg of off-white solid XI-13 was obtained, with a yield of 41.2%. MS (ESI (+) 70V) m / z [M+H] + :366.21.

[0298] Synthesis of (3,5-dichloro-4-hydroxyphenyl)(spiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-yl)methanone (I-E13)

[0299] Using intermediate XI-13 (150 mg, 0.41 mmol) as raw material and referring to the preparation method of compound I-A1, 79.63 mg of off-white solid I-E13 was obtained with a yield of 55.2%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 8.68 (s, 1H), 8.16 (d, J = 5.6Hz, 1H), 7.58 (s, 2H), 7.01 (d, J = 5. 5Hz,1H),3.93(s,2H),1.01(t,J=6.2Hz,2H),0.80(t,J=6.2Hz,2H).MS(ESI(+)70V)m / z[M+H] + :352.18.

[0300] Example 31: Synthesis of (3-chloro-4-hydroxy-5-nitrophenyl)(7-bromospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E14)

[0301] Synthesis of (3-chloro-4-methoxy-5-nitrophenyl)(7-bromospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (XI-14)

[0302] Using intermediate X-2 (100 mg, 0.45 mmol) and intermediate III-7 (130 mg, 0.56 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 96.6 mg of light yellow solid XI-14 was obtained, with a yield of 51.1%. MS (ESI (+) 70V) m / z [M+H] + :454.67.

[0303] Synthesis of (3-chloro-4-hydroxy-5-nitrophenyl)(7-bromospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E14)

[0304] Using intermediate XI-14 (140 mg, 0.33 mmol) as raw material, referring to the preparation method of compound I-A1, 119.7 mg of yellow solid I-E14 was obtained, with a yield of 88.2%. MS (ESI (+) 70V) m / z [M+H] + :440.65. 1H NMR (300MHz, DMSO-d6) δ (ppm): 8.04 (d, J = 2.3Hz, 1H), 7.83 (d, J = 2.3Hz, 1H), 7.76 (d, J = 2.4Hz, 1H), 7.21 (dd,J=8.7,2.4Hz,1H),6.86(d,J=8.8Hz,1H),3.86(s,2H),0.94(t,J=5.2Hz,2H),0.72(t,J=5.2Hz,2H).

[0305] Example 32: Synthesis of (3-chloro-4-hydroxy-5-nitrophenyl)(spiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-yl)methanone (I-E15)

[0306] Synthesis of (3-chloro-4-methoxy-5-nitrophenyl)(spiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-yl)methanone (XI-15)

[0307] Using intermediate X-3 (150 mg, 0.93 mmol) and intermediate III-7 (257 mg, 1.11 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 166.5 mg of off-white solid XI-15 was obtained, with a yield of 47.9%. MS (ESI (+) 70V) m / z [M+H] + :376.77.

[0308] Synthesis of (3-chloro-4-hydroxy-5-nitrophenyl)(spiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-yl)methanone (I-E15)

[0309] Using intermediate XI-15 (170 mg, 0.45 mmol) as raw material, referring to the preparation method of compound I-A1, 146.2 mg of yellow solid I-E15 was obtained, with a yield of 89.3%. MS (ESI (+) 70V) m / z [M+H] + :362.74. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 8.44 (s, 1H), 8.08 (d, J = 5.6Hz, 1H), 7.97 (d, J = 2.6Hz, 1H), 7.51 (d ,J=2.5Hz,1H),6.94(d,J=5.6Hz,1H),3.95(s,2H),1.00(t,J=6.1Hz,2H),0.80(t,J=6.2Hz,2H).

[0310] Example 33: Synthesis of (3,5-difluoro-4-hydroxyphenyl)(6-fluorospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E16)

[0311] Synthesis of (3,5-difluoro-4-methoxyphenyl)(6-fluorospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (XI-16)

[0312] Using 6-fluoro-3,4-dihydrospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane] (X-4, 150 mg, 0.84 mmol) and intermediate III-2 (189 mg, 1.0 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 100 mg of off-white solid XI-16 was obtained with a yield of 31.2%. MS (ESI (+) 70V) m / z [M+H] + :350.31.

[0313] Synthesis of (3,5-difluoro-4-hydroxyphenyl)(6-fluorospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E16)

[0314] Using intermediate XI-16 (160 mg, 0.49 mmol) as raw material, referring to the preparation method of compound I-A1, 56 mg of off-white solid I-E16 was obtained, with a yield of 36.5%. MS (ESI (+) 70V) m / z [M+H] + :336.28. 1 H NMR (300 MHz, DMSO-d 6 )δ(ppm):7.23(dd,J=12.0,3.0Hz,1H),7.08(dd,J=9.0,3.0Hz,2H),6.87(d,J=9.0Hz,2H),3.84(s,2H),0.92(t,J=6.0Hz,2H),0.70(t,J=6.0Hz,2H).

[0315] Example 34: Synthesis of (3,5-dichloro-4-hydroxyphenyl)(6-fluorospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E17)

[0316] Synthesis of (3,5-dichloro-4-methoxyphenyl)(6-fluorospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (XI-17)

[0317] Using intermediate X-4 (150 mg, 0.84 mmol) and intermediate III-3 (222 mg, 1.0 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 159.2 mg of off-white solid XI-17 was obtained, with a yield of 49.8%. MS (ESI (+) 70V) m / z [M+H] + :383.21.

[0318] Synthesis of (3,5-dichloro-4-hydroxyphenyl)(6-fluorospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E17)

[0319] Using intermediate XI-17 (85 mg, 0.22 mmol) as raw material and referring to the preparation method of compound I-A1, 30 mg of off-white solid I-E17 was obtained with a yield of 36.6%. 1 H NMR (500MHz, DMSO-d6) δ (ppm): 7.46 (s, 2H), 7.30 (d, J = 10.6Hz, 1H), 6.89 (d, J = 1.7Hz, 1H), 6.87 (d ,J=1.7Hz,1H),3.84(s,2H),0.93(t,J=5.6Hz,2H),0.72(t,J=5.6Hz,2H).MS(ESI(+)70V)m / z[M+H] + :368.02.

[0320] Example 35: Synthesis of (3,5-dibromo-4-hydroxyphenyl)(6-fluorospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E18)

[0321] Synthesis of (3,5-dibromo-4-methoxyphenyl)(6-fluorospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (XI-18)

[0322] Using intermediate X-4 (160 mg, 0.89 mmol) and intermediate III-5 (360 mg, 1.16 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 180 mg of off-white solid XI-18 was obtained with a yield of 42.8%. MS (ESI (+) 70V) m / z [M+H] + :472.12.

[0323] Synthesis of (3,5-dibromo-4-hydroxyphenyl)(6-fluorospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E18)

[0324] Using intermediate XI-18 (160 mg, 0.34 mmol) as raw material and referring to the preparation method of compound I-A1, 34 mg of off-white solid I-E18 was obtained with a yield of 19.5%. 1 H NMR (500MHz, DMSO-d6) δ (ppm): 7.53 (s, 2H), 7.14 (dd, J = 11.0, 2.8Hz, 1H), 6.90–6.78 (m, 2H),3.83(s,2H),0.92(t,J=5.7Hz,2H),0.72(t,J=5.7Hz,2H).MS(ESI(+)70V)m / z[M+H] + :458.09.

[0325] Example 36: Synthesis of (3-chloro-4-hydroxy-5-nitrophenyl)(6-fluorospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E19)

[0326] Synthesis of (3-chloro-4-methoxy-5-nitrophenyl)(6-fluorospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (XI-19)

[0327] Using intermediate X-4 (100 mg, 0.56 mmol) and intermediate III-7 (155 mg, 0.67 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 168.9 mg off-white solid XI-19 was obtained, with a yield of 77.1%. MS (ESI (+) 70V) m / z [M+H] + :393.77.

[0328] Synthesis of (3-chloro-4-hydroxy-5-nitrophenyl)(6-fluorospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E19)

[0329] Using intermediate XI-19 (100 mg, 0.26 mmol) as raw material and referring to the preparation method of compound I-A1, 88.2 mg of yellow solid I-E19 was obtained with a yield of 91.5%. 1 H NMR(500MHz,DMSO-d6)δ(ppm):8.07(d,J=2.2Hz,1H),7.94(d,J=2.2Hz,1H),7.50(d,J=11.0Hz,1H),6 .98–6.87(m,2H),3.86(s,2H),0.93(t,J=5.7Hz,2H),0.73(t,J=5.7Hz,2H).MS(ESI(+)70V)m / z[M+H] + :379.74.

[0330] Example 37: Synthesis of 5-(6-fluoro-3,4-dihydrospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4-carbonyl)-2-hydroxybenzonitrile (I-E20)

[0331] Synthesis of 5-(6-fluoro-3,4-dihydrospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4-carbonyl)-2-methoxybenzonitrile (XI-20)

[0332] Using intermediate X-4 (160 mg, 0.89 mmol) and intermediate 3-cyano-4-methoxybenzoic acid (III-10, 190 mg, 1.07 mmol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 210 mg of off-white solid XI-20, with a yield of 69.5%. MS (ESI (+) 70V) m / z [M+H] + :339.34.

[0333] Synthesis of 5-(6-fluoro-3,4-dihydrospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4-carbonyl)-2-hydroxybenzonitrile (I-E20)

[0334] Using intermediate XI-20 (184 mg, 0.54 mmol) as raw material, referring to the preparation method of compound I-A1, 50 mg of off-white solid I-E20 was obtained with a yield of 15.1%. MS (ESI (+) 70V) m / z [M+H] + :325.31. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 11.80 (s, 1H), 7.85 (d, J = 2.2Hz, 1H), 7.73–7.62 (m, 1H), 7.35 (d, J = 10.6Hz ,1H),7.07(d,J=8.7Hz,1H),6.96–6.85(m,2H),3.83(s,2H),0.94(t,J=5.2Hz,2H),0.72(t,J=5.2Hz,2H).

[0335] Example 38: Synthesis of (3-chloro-5-fluoro-4-hydroxyphenyl)(6-fluorospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E21)

[0336] Synthesis of (3-chloro-5-fluoro-4-methoxyphenyl)(6-fluorospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (XI-21)

[0337] Using intermediate X-4 (150 mg, 0.84 mmol) and 3-chloro-5-fluoro-4-methoxybenzoic acid (III-11, 206 mg, 1.0 mmol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 175 mg of off-white solid XI-21, with a yield of 57.2%. MS (ESI (+) 70V) m / z [M+H] + :366.76.

[0338] Synthesis of (3-chloro-5-fluoro-4-hydroxyphenyl)(6-fluorospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E21)

[0339] Using intermediate XI-21 (145 mg, 0.40 mmol) as raw material and referring to the preparation method of compound I-A1, 93 mg of off-white solid I-E21 was obtained with a yield of 66.7%. 1 H NMR(500MHz,DMSO-d6)δ(ppm):11.11(s,1H),7.45–7.38(m,3H),6.97–6.83(m,2H), 3.84(s,2H),0.93(t,J=5.7Hz,2H),0.72(t,J=5.7Hz,2H).MS(ESI(+)70V)m / z[M+H] + :352.73.

[0340] Example 39: Synthesis of (3,5-dichloro-4-hydroxyphenyl)(6-(trifluoromethyl)spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E22)

[0341] Synthesis of (3,5-dichloro-4-methoxyphenyl)(6-(trifluoromethyl)spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (XI-22)

[0342] Using 6-(trifluoromethyl)-3,4-dihydrospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane] (X-5, 100 mg, 0.44 mmol) and intermediate III-3 (116 mg, 0.52 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 136.6 mg of off-white solid XI-22 was obtained, with a yield of 72.4%. MS (ESI (+) 70V) m / z [M+H] + :433.22.

[0343] Synthesis of (3,5-dichloro-4-hydroxyphenyl)(6-(trifluoromethyl)spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E22)

[0344] Using intermediate XI-22 (80 mg, 0.19 mmol) as raw material, referring to the preparation method of compound I-A1, 56.5 mg of white solid I-E22 was obtained, with a yield of 73.0%. MS (ESI (+) 70V) m / z [M+H] + :419.19. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 10.92 (s, 1H), 7.96 (s, 1H), 7.59 (s, 2H), 7.41 (dd, J = 8.6, 2. 4Hz, 1H), 7.10 (d, J = 8.4Hz, 1H), 3.91 (s, 2H), 1.00 (t, J = 6.3Hz, 2H), 0.79 (t, J = 6.3Hz, 2H).

[0345] Example 40: Synthesis of (3,5-dibromo-4-hydroxyphenyl)(6-(trifluoromethyl)spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E23)

[0346] Synthesis of (3,5-dibromo-4-methoxyphenyl)(6-(trifluoromethyl)spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (XI-23)

[0347] Using intermediate X-5 (150 mg, 0.65 mmol) and intermediate III-5 (243 mg, 0.79 mmol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 170.4 mg off-white solid XI-23, with a yield of 50.0%. MS (ESI (+) 70V) m / z [M+H] + :522.13.

[0348] Synthesis of (3,5-dibromo-4-hydroxyphenyl)(6-(trifluoromethyl)spiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]-4(3H)-yl)methanone (I-E23)

[0349] Using intermediate XI-23 (170 mg, 0.33 mmol) as raw material, referring to the preparation method of compound I-A1, 109.8 mg of off-white solid I-E23 was obtained, with a yield of 66.4%. MS (ESI (+) 70V) m / z [M+H] + :508.10. 1H NMR (400MHz, DMSO-d6) δ (ppm): 10.69 (s, 1H), 7.94 (s, 1H), 7.74 (s, 1H), 7.71-7.62 (m, 1H), 7.41 (dd, J=8.7,2.3Hz,1H),7.09(d,J=8.6Hz,1H),3.91(s,2H),1.00(t,J=5.1Hz,2H),0.78(t,J=5.1Hz,2H).

[0350] Example 41: Synthesis of (3,5-dibromo-4-hydroxyphenyl)(spiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-yl)methanone (I-E24)

[0351] Synthesis of (3,5-dibromo-4-methoxyphenyl)(spiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-yl)methanone (XI-24)

[0352] Using intermediate X-3 (150 mg, 0.93 mmol) and intermediate III-5 (343.97 mg, 1.11 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 169.98 mg of off-white solid XI-24 was obtained, with a yield of 40.47%. MS (ESI (+) 70V) m / z [M+H] + :455.12.

[0353] Synthesis of (3,5-dibromo-4-hydroxyphenyl)(spiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-yl)methanone (I-E24)

[0354] Using intermediate XI-24 (65 mg, 0.14 mmol) as raw material, referring to the preparation method of compound I-A1, 42.99 mg of off-white solid I-E24 was obtained, with a yield of 68.25%. MS (ESI (+) 70V) m / z [M+H] + :441.09. 1 H NMR (400MHz, DMSO-d6) δ (ppm): 8.61 (s, 1H), 8.12 (d, J = 5.5Hz, 1H), 7.73 (s, 2H), 6.95(d,J=5.5Hz,1H),3.92(s,2H),1.01(t,J=6.6Hz,2H),0.79(t,J=6.6Hz,2H).

[0355] Example 42: Synthesis of (3-chloro-5-fluoro-4-hydroxyphenyl)(spiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-yl)methanone (I-E25)

[0356] Synthesis of (3-chloro-5-fluoro-4-methoxyphenyl)(spiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-yl)methanone (XI-25)

[0357] Using intermediate X-3 (150 mg, 0.93 mmol) and intermediate III-11 (227.08 mg, 1.11 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 162.54 mg of off-white solid XI-25 was obtained, with a yield of 50.39%. MS (ESI (+) 70V) m / z [M+H] + :349.76.

[0358] Synthesis of (3-chloro-5-fluoro-4-hydroxyphenyl)(spiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-yl)methanone (I-E25)

[0359] Using intermediate XI-25 (80 mg, 0.23 mmol) as raw material, referring to the preparation method of compound I-A1, 83 mg of off-white solid I-E25 was obtained, with a yield of 69.03%. MS (ESI (+) 70V) m / z [M+H] + :335.73. 1 H NMR (400MHz, DMSO-d6) δ (ppm): 11.30 (s, 1H), 8.65 (s, 1H), 8.15 (s, 1H), 7.44 (d, J = 2.52Hz, 1H), 7.41 (d,J=1.96Hz,1H),6.99(d,J=5.4Hz,1H),3.93(s,2H),1.02(t,J=6.5Hz,2H),0.78(t,J=6.5Hz,2H).

[0360] Example 43: Synthesis of (3-bromo-5-chloro-4-hydroxyphenyl)(spiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-yl)methanone (I-E26)

[0361] Synthesis of (3-bromo-5-chloro-4-methoxyphenyl)(spiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-yl)methanone (XI-26)

[0362] Using intermediate X-3 (150 mg, 0.93 mmol) and 3-bromo-5-chloro-4-methoxybenzoic acid (III-12, 295 mg, 1.11 mmol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 63 mg of off-white solid XI-26, with a yield of 16.63%. MS (ESI (+) 70V) m / z [M+H] + :410.66.

[0363] Synthesis of (3-bromo-5-chloro-4-hydroxyphenyl)(spiro[cyclopropane-1,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-yl)methanone (I-E26)

[0364] Using intermediate XI-26 (50 mg, 0.12 mmol) as raw material, referring to the preparation method of compound I-A1, 48 mg of off-white solid I-E26 was obtained with a yield of 99.4%. MS (ESI (+) 70V) m / z [M+H] + :395.64. 1 H NMR (400MHz, DMSO-d6) δ (ppm): 8.59 (s, 1H), 8.12 (d, J = 5.6Hz, 1H), 7.66 (d, J = 2.2Hz, 1H), 7.56 (d ,J=2.1Hz,1H),6.95(d,J=5.6Hz,1H),3.92(s,2H),1.01(t,J=6.5Hz,2H),0.79(t,J=6.6Hz,2H).

[0365] Example 44: Synthesis of (3,5-difluoro-4-hydroxyphenyl)(spiro[cyclopropane-1,3'-pyrido[2,3-b][1,4]oxazine]-1'(2'H)-yl)methanone (I-E27)

[0366] Synthesis of (3,5-difluoro-4-methoxyphenyl)(spiro[cyclopropane-1,3'-pyrido[2,3-b][1,4]oxazine]-1'(2'H)-yl)methanone (XI-27)

[0367] Using 1',2'-dihydrospiro[cyclopropane-1,3'-pyrido[2,3-b][1,4]oxazine] (intermediate X-6, 100 mg, 0.62 mmol) and intermediate III-2 (127.6 mg, 0.68 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 115.7 mg of off-white solid XI-27 was obtained, with a yield of 56.5%. MS (ESI (+) 70V) m / z [M+H] + :333.31.

[0368] Synthesis of (3,5-difluoro-4-hydroxyphenyl)(spiro[cyclopropane-1,3'-pyrido[2,3-b][1,4]oxazine]-1'(2'H)-yl)methanone (I-E27)

[0369] Using intermediate XI-27 (163 mg, 0.49 mmol) as raw material, referring to the preparation method of compound I-A1, 122.4 mg of off-white solid I-E27 was obtained, with a yield of 78.4%. MS (ESI (+) 70V) m / z [M+H] + :319.28. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 10.98 (s, 1H), 7.96 (d, J = 5.6Hz, 2H), 7.30 (dd, J = 6.9, 1.8Hz, 2H), 7.03 (dd, J=7.8, 4.9Hz, 1H), 3.88 (s, 2H), 1.01 (t, J=5.2Hz, 2H), 0.76 (t, J=5.2Hz, 2H).

[0370] Example 45: Synthesis of (3,5-dichloro-4-hydroxyphenyl)(spiro[cyclopropane-1,3'-pyrido[2,3-b][1,4]oxazine]-1'(2'H)-yl)methanone (I-E28)

[0371] Synthesis of (3,5-dichloro-4-methoxyphenyl)(spiro[cyclopropane-1,3'-pyrido[2,3-b][1,4]oxazine]-1'(2'H)-yl)methanone (XI-28)

[0372] Using intermediate X-6 (100 mg, 0.62 mmol) and intermediate III-3 (149.9 mg, 0.68 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 177.5 mg of light yellow oily liquid XI-28 was obtained, with a yield of 78.8%. MS (ESI (+) 70V) m / z [M+H] + :366.21.

[0373] Synthesis of (3,5-dichloro-4-hydroxyphenyl)(spiro[cyclopropane-1,3'-pyrido[2,3-b][1,4]oxazine]-1'(2'H)-yl)methanone (I-E28)

[0374] Using intermediate XI-28 (140 mg, 0.38 mmol) as raw material, referring to the preparation method of compound I-A1, 99.8 mg of off-white solid I-E28 was obtained, with a yield of 74.2%. MS (ESI (+) 70V) m / z [M+H] + :352.18. 1H NMR(300MHz,DMSO-d6)δ(ppm):10.88(s,1H),7.99-7.95(m,2H),7.58(s,2H),7.03 (dd,J=7.9,4.8Hz,1H),3.89(s,2H),1.01(t,J=5.2Hz,2H),0.77(t,J=5.2Hz,2H).

[0375] Example 46: Synthesis of (3,5-dibromo-4-hydroxyphenyl)(spiro[cyclopropane-1,3'-pyrido[2,3-b][1,4]oxazine]-1'(2'H)-yl)methanone (I-E29)

[0376] Synthesis of (3,5-dibromo-4-methoxyphenyl)(spiro[cyclopropane-1,3'-pyrido[2,3-b][1,4]oxazine]-1'(2'H)-yl)methanone (XI-29)

[0377] Using intermediate X-6 (100 mg, 0.62 mmol) and intermediate III-5 (210.14 mg, 0.68 mmol) as raw materials, referring to the preparation method of intermediate IV-1, 105.92 mg of light yellow oily liquid XI-29 was obtained, with a yield of 37.8%. MS (ESI (+) 70V) m / z [M+H] + :455.12.

[0378] Synthesis of (3,5-dibromo-4-hydroxyphenyl)(spiro[cyclopropane-1,3'-pyrido[2,3-b][1,4]oxazine]-1'(2'H)-yl)methanone (I-E29)

[0379] Using intermediate XI-29 (160 mg, 0.35 mmol) as raw material, referring to the preparation method of compound I-A1, 107.3 mg of off-white solid I-E29 was obtained, with a yield of 69.2%. MS (ESI (+) 70V) m / z [M+H] + :441.09. 1 H NMR(300MHz,DMSO-d6)δ(ppm):10.65(s,1H),8.04–7.89(m,2H),7.73(s,2H),7.03 (dd,J=7.8,4.9Hz,1H),3.89(s,2H),1.01(t,J=5.1Hz,2H),0.78(t,J=5.1Hz,2H).

[0380] Example 47: Synthesis of (3-chloro-4-hydroxy-5-nitrophenyl)(spiro[cyclopropane-1,3'-pyrido[2,3-b][1,4]oxazine]-1'(2'H)-yl)methanone (I-E30)

[0381] Synthesis of (3-chloro-4-methoxy-5-nitrophenyl)(spiro[cyclopropane-1,3'-pyrido[2,3-b][1,4]oxazine]-1'(2'H)-yl)methanone (XI-30)

[0382] Using intermediate X-6 (200 mg, 1.23 mmol) and intermediate III-7 (342.75 mg, 1.48 mmol) as raw materials, refer to the preparation method of intermediate IV-1 to obtain 199.7 mg off-white solid XI-30, with a yield of 43.1%. MS (ESI (+) 70V) m / z [M+H] + :376.06.

[0383] Synthesis of (3-chloro-4-hydroxy-5-nitrophenyl)(spiro[cyclopropane-1,3'-pyrido[2,3-b][1,4]oxazine]-1'(2'H)-yl)methanone (I-E30)

[0384] Using intermediate XI-30 (170 mg, 0.45 mmol) as raw material, referring to the preparation method of compound I-A1, 92.4 mg of yellow solid I-E30 was obtained, with a yield of 56.5%. MS (ESI (+) 70V) m / z [M+H] + :362.74. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 8.03-7.96 (m, 3H), 7.87 (s, 1H), 7.05 (dd, J = 7.8, 4.7Hz, 1H), 3.91 (s, 2H), 1.01 (t, J = 6.1Hz, 2H), 0.78 (t, J = 6.1Hz, 2H).

[0385] Example 48: In vitro inhibitory activity test of the compounds of the present invention on hURAT1

[0386] 1. Cell Culture and Inoculation

[0387] HEK-293T cell line (from Wise Chemical Research Co., Ltd.) stably expressing hURAT1 was cultured in a medium composed of: DMEM medium + 10% fetal bovine serum + 500μg / mL G418 + 1% P / S. When the cells grew to 80%, the medium was discarded, and the cells were washed once with PBS, and then trypsin was added for digestion. When the cells were detached from the wall, the medium was added, and the cells were blown to detach, and the cells were collected by centrifugation, and the medium was added to the cell suspension. The cell density was adjusted to 7×10 5 / mL, and then inoculated into a 96-well cell culture plate at a volume of 100 μL / well and cultured for 12 to 24 hours.

[0388] 2. Compound Preparation

[0389] The quality control compound benzbromarone was set up. The compound was prepared into a 20 mM stock solution with DMSO and then DMSO and Cl - Free HBSS buffer (including: 125mM sodium D-gluconate, 4.8mM potassium D-gluconate, 1.3mM calcium D-gluconate, 1.2mM KH2PO4, 1.2mM MgSO4, 5.6mM glucose, 25mM HEPES (pH7.4)) (volume ratio of 1:49) was used to dilute the stock solution to a concentration of 2μM, and then 25μL / well of 0.1μCi / mL 14 C-uric acid buffer and 25 μL / well of 2 μM compound were prepared to 1 μM compound for use.

[0390] 3. 14 C-uric acid uptake in cells stably expressing hURAT1

[0391] After the cells in the 96-well plate have attached to the wall, the absorption test can be performed. - Wash the cells once with free HBSS buffer. Aspirate each well and immediately add 50 μL / well containing the corresponding compound and 0.1 μCi / mL 14 C-uric acid solution. The plate with the added compounds was incubated in a 37°C incubator for 5 minutes.

[0392] Immediately add 150 μL of ice-cold Cl-free HBSS buffer to each well to terminate absorption. Wash each well three times with buffer. During the washing process, try to avoid cell shedding. Add 50 μL of 100 mM NaOH lysis solution to each well and place it on an oscillator at 900 rpm for 5 minutes. Add 150 μL of scintillation fluid Microsint40 to each well and oscillate at 900 rpm for 5 minutes. Finally, send the microplate to the MicroBeta2 (manufactured by PerkinElmer) instrument to measure the radioactivity. The radioactivity was measured at compound dilution concentrations of 3 μmol / L, 1 μmol / L, 0.33 μmol / L, 0.11 μmol / L, 0.037 μmol / L, 0.012 μmol / L, 0.004 μmol / L, and 0.0014 μmol / L, respectively, and the data were analyzed, and the IC of each compound was calculated using GraphPadPrism 5 software. 50 .

[0393] 4. Test Results

[0394] Table 1 In vitro inhibitory activity of the compounds of the present invention on hURAT1

[0395]

[0396]

[0397] Note: At 100nM, the inhibition rate ranges of A, B and C are as follows: A≥75%, 50%≤B<75%, C<50%.

[0398] The results in Table 1 show that at a concentration of 100 nM, the compounds of the present invention have strong inhibitory activity against hURAT1, especially compounds I-E2, I-E3, I-E5, I-E7, I-E9, I-E17, I-E18, I-E19, I-E24 and I-E26, whose inhibition rates against hURAT1 at a concentration of 100 nM are over 75%.

[0399] Some compounds with higher inhibition rates were selected and their IC values ​​for hURAT1 were determined. 50 The results are shown in Table 2.

[0400] Table 2 IC values ​​of some compounds of the present invention for hURAT1 50 Determination

[0401]

[0402] Note: The ranges of A, B and C are as follows: A≤30nM, 30nM<B≤200nM, 200nM<C≤1000nM.

[0403] The results in Table 2 show that the IC values ​​of most of the tested compounds are 50 No more than 200 nM, among which compounds I-E3, I-E5, I-E7, I-E17 to I-E19, I-E21 and I-E24 had IC 50 Not more than 30nM.

[0404] Example 49: Experimental study on the selective inhibitory activity of compound I-E24 of the present invention on uric acid transporters

[0405] 1. Breast cancer resistance protein (BCRP / ABCG2) inhibitory activity experiment

[0406] Test system: expressing human BCRP vesicles (purchased from GenoMembrane, Japan)

[0407] Incubation conditions: incubation time: 10 min; temperature: 37°C; test concentrations: 100, 50, 10, 3 and 0.1 μM;

[0408] Experimental and control group settings: Experimental group: different concentrations of I-E24 were pre-incubated with human BCRP vesicles at 37°C for 5 minutes, and then incubated with fluorescent yellow probe substrate at 37°C for 5 minutes under the condition of adding ATP or AMP respectively; Positive control group: human BCRP vesicles were pre-incubated with Dotinurad at 37°C for 5 minutes, and then incubated with probe substrate at 37°C for 5 minutes under the condition of adding ATP or AMP respectively;

[0409] Experimental steps: 1) Pre-incubate the test substance with vesicles expressing human BCRP at 37°C for 5 minutes, and then incubate with the probe substrate at 37°C for 5 minutes with the addition of ATP or AMP respectively; 2) Terminate the test with pre-cooled stop and wash buffer Buffer B2 (400mM MOPS-Tris / 700mM KCl mixture) (BCRP). Transfer the test sample to a 96-well filter plate and filter with a vacuum pump. Then wash repeatedly 5 times with 0.2mL pre-cooled Buffer B2 (BCRP). Dissolve the vesicles on the filter plate with 50μL 10% SDS and collect them. Centrifuge the collected liquid at 2000 rpm for 2 minutes, collect the supernatant, and repeat the above operation; 3) Combine the two supernatants together, mix well, obtain about 100μL of liquid, and add an equal volume of DMSO. Use a fluorescence microplate reader to quantitatively detect the fluorescence intensity of fluorescent yellow LFY (excitation light is 428nm, emission light is 536nm).

[0410] 2. Organic anion transporter 1 (OAT1) and organic anion transporter 3 (OAT3) inhibitory activity test

[0411] Test system: HEK293 cells expressing human OAT1 and OAT3 transporters (purchased from GenoMembrane, Japan)

[0412] Incubation conditions: incubation time: 10 min; temperature: 37°C; test concentrations: 100, 50, 10, 3 and 0.1 μM;

[0413] Experimental and control group settings: Experimental group: a mixed solution of different concentrations of I-E24 and the probe substrate p-aminohippuric acid (OAT1 probe substrate) / estrone 3-sulfate (OAT3 probe substrate) was incubated with different transporter cells at 37°C for 10 minutes; Positive control group: a mixed solution of Dotinurad and the probe substrate was incubated with different transporter cells at 37°C for 10 minutes.

[0414] Experimental steps: 1) HEK293 cells expressing human OAT1 and OAT3 transporters were cultured in DMEM medium (purchased from Gibco, catalog number 11885-084) at 37°C and 5% CO2. 5 10 cells / well were seeded in a 96-well plate. 2) Before the test, the culture medium was aspirated from the culture plate, and the cells were washed twice with 37°C preheated transport buffer (pH=7.4, containing 125mM NaCl / 4.8mM KCl / 5.6mM D-(+)-glucose / 1.2mM CaCl2 / 1.2mM KH2PO4 / 1.2mM MgSO4 / 25mM HEPES), 0.1mL / well each time. The buffer after the second wash was left in the culture plate and equilibrated at 37°C for 5 minutes. 3) Aspirate the buffer, add 0.05 mL of preheated substrate p-aminohippuric acid (OAT1 probe substrate) / estrone 3-sulfate (OAT3 probe substrate) and a mixed solution of different concentrations of I-E24 or Dotinurad, and incubate at 37°C for 10 minutes; after the incubation, immediately aspirate the incubation solution and wash 3 times with pre-cooled transport buffer, 0.1 mL / well each time. 4) After washing, add 0.1 mL of distilled water to each well, and freeze and thaw repeatedly with liquid nitrogen 3 times (-196°C to -37°C) to completely lyse the cells. 5) Take part of the lysate and mix it with methanol containing the internal standard (tolbutamide) in a ratio of 1:4. After the precipitate is precipitated, transfer it to a new 1.5 mL centrifuge tube, centrifuge at 12000 rpm, 4°C for 5 minutes, collect the supernatant, and use LC-MS / MS method to quantitatively detect the content of the probe substrate in each sample. 6) Take a certain amount of lysate and use The BCA Protein Assay Kit measures the cellular protein concentration in samples.

[0415] 3. Test results

[0416] Table 3 IC of the compounds of the present invention on uric acid transporter 50 Determination

[0417]

[0418] The results in Table 3 show that compound I-E24 inhibited the uptake of uric acid by transporters other than URAT1 (BRCP (ABCG2), OAT1, OAT3) in a concentration-dependent manner. 50 The IC values ​​of Dotinurad for (BRCP (ABCG2), OAT1, OAT3) were 37.1μM, 6.16μM and 6.62μM respectively; 50The selectivity of Dotinurad for URAT1 inhibition is 311 times, 68 times and 153 times, respectively, compared with the inhibition of transporters BRCP (ABCG2), OAT1 and OAT3, while the selectivity of compound I-E24 for URAT1 inhibition is as high as 7894 times, 1311 times and 1408 times, respectively. In summary, compound I-E24 can inhibit the activity of URAT1 with high selectivity.

Claims

1. A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof: or a stereoisomer, solvate, prodrug, isotope-labeled substance, or pharmaceutically acceptable salt thereof, in, X 1 Selected from O, S, Se, NR 5 , CHR 5 , SO, SO 2 Or S(O)=NR 5 , where R 5 Selected from H, C 1 ~C 6 Alkyl, C 2 ~C 6 Alkenyl, C 2 ~C 6 Alkynyl, C 3 ~C 6 Cycloalkyl, C 3 ~C 6 Cycloalkyl substituted C 1 ~C 6 Alkyl or C 1 ~C 6 Alkanoyl; X 2 , X 3 , X 4 , X 5 Each independently selected from N or CR 6 , where R 6 Each occurrence is independently selected from H, halogen, cyano, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkyl, or C 1 ~C 6 Haloalkoxy; A, B, Y, and Z are each independently selected from N or CR 7 , where R 7 is independently selected at each occurrence from H, halogen, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Haloalkoxy, cyano, nitro, C 3 ~C 6 Cycloalkyl, C 3 ~C 6 Cycloalkyl substituted C 1 ~C 6 Alkyl, C 3 ~C 6 Cycloalkyloxy, C 3 ~C 6 Cycloalkyl substituted C 1 ~C 6 Alkoxy, COR 8 , CO 2 R 8 ,CONR 8 R 8’ NR 8 R 8’ , SOR 9 or SO 2 R 9 , R 8 or R 8’ Each independently selected from H, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, C 3 ~C 6 Cycloalkyl, or C 3 ~C 6 Cycloalkyl substituted C 1 ~C 6 Alkyl; R 9 Selected from C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, C 3 ~C 6 Cycloalkyl, or C 3 ~C 6 Cycloalkyl substituted C 1 ~C 6 alkyl; R 1 , R 2 , R 3 or R 4 are each independently selected from H, optionally substituted C 1 ~C 6 Alkyl, optionally substituted C 2 ~C 6 Alkenyl, optionally substituted C 2 ~C 6 Alkynyl, optionally substituted C 3 ~C 6 Cycloalkyl, optionally substituted C 6 ~C 10 aryl, optionally substituted 5-membered or 6-membered heteroaryl, optionally substituted 3-membered to 6-membered heterocyclyl, the C 1 ~C 6 Alkyl, C 2 ~C 6 Alkenyl, C 2 ~C 6 Alkynyl, C 6 ~C 10 Aryl, 5-membered or 6-membered heteroaryl, 3-membered to 6-membered heterocyclyl are optionally substituted by a group selected from the group consisting of H, halogen, OR 5 NR 8 R 8’ , C 3 ~C 6 Cycloalkyl, C 3 ~C 6 Cycloalkyl substituted C 1 ~C 6 Alkyl, CO 2 R 8 or CONR 8 R 8’ ;or R 1 and R 2 , R 2 and R 3 , R 3 and R 4 Together with the carbon atom to which it is attached, it forms an optionally substituted C 3 ~C 6 carbocyclic or optionally substituted 3- to 6-membered heterocyclic ring, wherein 3 ~C 6 The carbocyclic ring or the 3- to 6-membered heterocyclic ring is optionally substituted by a group selected from the group consisting of H, halogen, C 1 ~C 6 Alkyl, OR 5 NR 8 R 8’ , C 3 ~C 6 Cycloalkyl, C 3 ~C 6 Cycloalkyl substituted C 1 ~C 6 Alkyl, CO 2 R 8 or CONR 8 R 8’ , the condition is R 1 , R 2 , R 3 and R 4 Not forming a carbocyclic ring or a heterocyclic ring at the same time; Q is selected from CH 2 , CO, SO or SO 2 .

2. The compound according to claim 1 or its stereoisomer, solvate, prodrug, isotope-labeled substance, and pharmaceutically acceptable salt, in: X 1 Selected from O, S, SO, SO 2 Or S(O)=NR 5 , where R 5 Selected from H, C 1 ~C 3 Alkyl, C 3 ~C 6 Cycloalkyl. X 2 , X 3 , X 4 , X 5 Each independently selected from N or CR 6 , where R 6 is independently selected at each occurrence from H, F, Cl, Br, cyano, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2,2-trifluoroethyl, 1,1,-difluoroethyl, trifluoromethoxy, difluoromethoxy, monofluoromethoxy, 2,2,2-trifluoroethoxy, 1,1,-difluoroethoxy; A, B, Y, and Z are each independently selected from N or CR 7 , where R 7 is independently selected at each occurrence from H, halogen, C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 Haloalkyl, C 1 ~C 3 Haloalkoxy, cyano, nitro, cyclopropyl, cyclopropyl-CH 2 -, cyclopropyloxy, cyclopropyl-CH 2 O-、COR 8 , CO 2 R 8 ,CONR 8 R 8’ NR 8 R 8’ , SOR 9 or SO 2 R 9 , R 8 or R 8’ Each is independently selected from H, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1-difluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl-CH 2 -, cyclobutyl-CH 2 -, cyclopentyl-CH 2 -, or cyclohexyl-CH 2 -; R 9 Selected from methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1-difluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl-CH 2 -, cyclobutyl-CH 2 -, cyclopentyl-CH 2 -, or cyclohexyl-CH 2 -.

3. The compound according to claim 1 or its stereoisomer, solvate, prodrug, isotope-labeled substance, and pharmaceutically acceptable salt, in: X 2 , X 3 , X 4 , X 5 are each independently selected from N or CH; A, B, Y, and Z are each independently selected from N or CR 7 , where R 7 is independently selected at each occurrence from H, halogen, C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 Haloalkyl, C 1 ~C 3 Haloalkoxy, cyano, nitro, cyclopropyl, cyclopropyl-CH 2 -, cyclopropyloxy, cyclopropyl-CH 2 O-、CO 2 CH 3 , CO 2 C 2 H 5 ,CONH 2 or CONHCH 3 .

4. The compound according to any one of claims 1 to 3 or its stereoisomer, solvate, prodrug, isotope-labeled substance, and pharmaceutically acceptable salt, in: R 1 , R 2 , R 3 or R 4 are each independently selected from H, optionally substituted C 1 ~C 3 Alkyl, optionally substituted C 2 ~C 3 Alkenyl, optionally substituted C 2 ~C 3 Alkynyl, optionally substituted C 3 ~C 6 cycloalkyl, optionally substituted phenyl, optionally substituted 5-membered or 6-membered heteroaryl, optionally substituted 3-membered to 6-membered heterocyclyl, the C 1 ~C 3 Alkyl, C 2 ~C 3 Alkenyl, C 2 ~C 3 Alkynyl, C 3 ~C 6 Cycloalkyl, phenyl, 5-membered or 6-membered heteroaryl, 3-membered to 6-membered heterocyclyl are optionally substituted by a group selected from the group consisting of H, halogen, OR 5 NR 8 R 8’ , C 3 ~C 6 Cycloalkyl, C 3 ~C 6 Cycloalkyl substituted C 1~ C 3 Alkyl, CO 2 R 8 or CONR 8 R 8’ ;or R 1 and R 2 , R 2 and R 3 , R 3 and R 4 Together with the carbon atom to which it is attached, it forms an optionally substituted C 3 ~C 6 carbocyclic or optionally substituted 3- to 6-membered heterocyclic ring, wherein 3 ~C 6 The carbocyclic ring or the 3- to 6-membered heterocyclic ring is optionally substituted by a group selected from the group consisting of H, halogen, C 1 ~C 6 Alkyl, OR 5 NR 8 R 8’ , C 3 ~C 6 Cycloalkyl, C 3 ~C 6 Cycloalkyl substituted C 1 ~C 3 Alkyl, CO 2 R 8 or CONR 8 R 8’ , the condition is R 1 , R 2 , R 3 and R 4 A carbocyclic ring or a heterocyclic ring cannot be formed at the same time.

5. The compound according to claim 4 or its stereoisomer, solvate, prodrug, isotope-labeled substance, and pharmaceutically acceptable salt, in: R 1 , R 2 , R 3 or R 4 each independently selected from H, methyl, ethyl, n-propyl, isopropyl, vinyl, propenyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, azetidinyl, oxetanyl, tetrahydropyrrolyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydroimidazolyl, tetrahydropyrazolyl, tetrahydrooxazolyl, tetrahydrothiazolyl, dioxanyl, morpholinyl, furanyl, imidazolyl, pyrazolyl, pyrrolyl, thienyl, thiazolyl, optionally substituted with a group selected from H, halogen, OR 5 NR 8 R 8’ , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C 3 ~C 6 Cycloalkyl-CH 2 -、CO 2 R 8 or CONR 8 R 8’ ;or R 1 and R 2 , R 2 and R 3 , R 3 and R 4 Together with the carbon atom to which it is attached, it forms an optionally substituted cyclopropane ring, cyclobutane ring, cyclopentane ring, cyclohexane ring, azetidine ring, oxetane ring, tetrahydropyrrole ring, piperidine ring, tetrahydrofuran ring, tetrahydropyran ring, tetrahydrothiophene ring, tetrahydrothiopyran ring, tetrahydroimidazole ring, tetrahydropyrazole ring, tetrahydrooxazole ring, tetrahydrothiazole ring, dioxane ring, morpholine ring, which is optionally substituted by a group selected from the following: H, halogen, OR 5 , C 1 ~C 6 Alkyl, NR 8 R 8’ , C 3 ~C 6 Cycloalkyl, C 3 ~C 6 Cycloalkyl substituted C 1 ~C 3 Alkyl, CO 2 R 8 or CONR 8 R 8’ , the condition is R 1 , R 2 , R 3 and R 4 The above-mentioned carbocyclic ring or heterocyclic ring is not formed at the same time.

6. The compound according to any one of claims 1 to 5, which is a compound represented by formula (II) or formula (II'): or its stereoisomers, solvates, prodrugs, isotope-labeled substances, and pharmaceutically acceptable salts, wherein X 1 , R 1 , R 2 , R 3 , R 4 , A, B, Y, Z, Q are as defined in any one of claims 1-5.

7. The compound according to any one of claims 1 to 5, which is a compound represented by formula (III) or formula (III'): or its stereoisomers, solvates, prodrugs, isotope-labeled substances, and pharmaceutically acceptable salts, wherein X 1 , R 1 , R 2 , A, B, Y, Z, Q are as defined in any one of claims 1-5.

8. The compound according to any one of claims 1 to 5, which is a compound represented by formula (IV) or formula (IV'): or its stereoisomers, solvates, prodrugs, isotope-labeled substances, and pharmaceutically acceptable salts, wherein X 1 , R 1 , R 2 , A, B, Y, Z are as defined in any one of claims 1-5.

9. The compound according to claim 1, which is selected from: or a stereoisomer, solvate, prodrug, isotope-labeled substance, or a pharmaceutically acceptable salt thereof. 10 . A pharmaceutical composition comprising the compound according to claim 1 , or a stereoisomer, solvate, prodrug, isotope-labeled substance, pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

11. Use of the compound according to any one of claims 1 to 9 or its stereoisomer, solvate, prodrug, isotope-labeled substance and pharmaceutically acceptable salt in the preparation of URAT1 inhibitor drugs.

12. Use of the compound according to any one of claims 1 to 9 or its stereoisomers, solvates, prodrugs, isotope-labeled substances and pharmaceutically acceptable salts in the preparation of drugs for treating diseases such as gout and hyperuricemia.